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ABSTRACT 
Insulin resistance is one of the major defects of type 2 diabetes. Liver, muscle and adipose 
tissue are the major sites responsive to the regulation of glucose homeostasis in response to 
insulin action. It has been demonstrated that hepatic insulin resistance occurs prior to 
peripheral insulin resistance. Excess lipid accumulation from dietary fat and de novo 
lipogenesis (DNL) has been suggested to be a trigger of hepatic insulin resistance. In the past 
decade, endoplasmic reticulum (ER) stress emerges to play a role in lipid metabolism and 
insulin resistance in the liver. However, the mechanisms of the development of insulin 
resistance that related to either lipid accumulation or ER stress remain unclear. Several 
pathways have been proposed to link lipid accumulation, ER stress and insulin resistance in 
the liver, such as JNK which is suggested to be activated by ER stress and affect insulin 
sensitivity negatively.  
The aims of the thesis were to investigate: 1) the role of ER stress in lipid synthesize 
(lipogenesis) and the development of lipid-related insulin resistance in the liver and, 2) the 
effect that lipogenesis and ER stress have on each other.  
The first study was designed to determine the contribution of either ER stress or lipid 
accumulation to the onset of hepatic insulin resistance induced by high fructose (HFru) 
feeding in mice. After feeding with high fructose for one day, ER stress was activated only in 
inositol-requiring protein 1 (IRE1)/X-box protein 1 (XBP1) branch of the unfolded protein 
response (UPR) pathways. Simultaneously, the expression of lipogenic transcription factors 
and enzymes was upregulated and the lipid content in the liver was increased. Besides the 
absence of glucose intolerance, insulin-stimulated phosphorylation of Akt was suppressed. 
Blocking IRE1 activity with the chemical chaperone tauroursodeoxycholic acid (TUDCA) 
abolished fructose-dependent increases in JNK activity and IRS serine phosphorylation, and 
protected insulin-stimulated Akt phosphorylation without altering hepatic steatosis or protein 
 xvi 
 
kinase C (PKC) ε, a key enzyme involved in lipid-induced insulin resistance. These data 
together suggest that activation of JNK rather than lipid accumulation is a key early trigger of 
ER stress related insulin resistance induced by HFru feeding in the liver. In addition, 
activation of ER stress and lipogenesis closely correlated in response to HFru feeding.  
To interrogate the role of either increasing lipid accumulation or activation of JNK and IKK 
in hepatic insulin resistance induced by high fructose, a hepatic steatosis-independent ER 
stress model was developed. Animals were fed with high fructose diet for 2 weeks. 
Fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, was 
administrated to reduce lipid accumulation while maintaining elevated DNL in the liver. 
Fenofibrate administration completely eliminated HFru-induced glucose intolerance and 
hepatic steatosis and insulin signal transduction. Both IRE1/XBP1 and PKP-like endoplasmic 
reticulum kinase (PERK)/ Eukaryotic translation initiator factor 2α (eIF2α) branches were 
activated. Fenofibrate treatment markedly increased fatty acid oxidation and eliminated the 
accumulation of diacyglycerols (DAG) which is known to have a negative impact on insulin 
signaling. Despite the marked activation of UPR signaling, neither c-Jun NH2-terminal kinase 
(JNK) nor IκB kinase (IKK) was activated. These data suggest that lipid accumulation, rather 
than JNK or IKK activation, is pivotal for ER stress to cause hepatic insulin resistance when 
the mice were challenged with  HFru diet for a long time.  
In a different series of studies, mice were fed with a high fat (HFat) diet for either 1 day or 2 
weeks. Hepatic DAG content was increased in the HFat-fed animals, indicating that the 
hepatic insulin resistance could result from elevated DAG level. Interestingly, unlike HFru-
fed mice, HFat-fed mice did not show ER stress activation. The HFat-fed mice showed that 
insulin resistance was induced via different mechanisms in the face of fatty acid influx. These 
finding indicate that ER stress is unlikely to result from lipid accumulation.  
 xvii 
 
To investigate the interaction between ER stress and lipogenesis, we utilized fructose to 
induce ER stress in cultured cells, aimed to mimic the HFru-feeding model in animals. 
Betulin, which can suppress the activity of lipogenic transcription factor sterol regulatory 
element binding protein (SREBP1c) was applied to cells treated with fructose. With the 
presence of betulin, lipogenic enzymes levels were significantly diminished. However, the 
magnified fructose-induced phosphorylation of IRE1 and eIF2α was not altered, suggesting 
that increasing lipogenesis does not contribute to the activation of IRE1 and PERK branches 
under the condition induced by fructose oversupply.  
In summary, ER stress and DNL both contribute to HFru-induced hepatic insulin resistance. It 
seems that ER stress is more important in the early stage of the development of insulin 
resistance in the liver. Accordingly, lipid accumulation plays a critical role later on. The 
predominantly negative effect of JNK activation induced by IRE1 might be overcome by the 
persistently increasing lipid accumulation, possibly becomes a secondary inducer of insulin 
resistance in the long term. However, the relationship between these two mechanistic 
pathways and its implication in insulin resistance seems very complex and more studies are 
required. 
The significance of these studies not only lies in bridging gaps in the current literature, but 
also in providing the basis for drug design and discovery towards preventing and treating type 
2 diabetes. 
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1.1 Diabetes and insulin resistance  
1.1.1 Diabetes 
Diabetes is characterized by hyperglycemia (fasting blood glucose level ≥ 7.0 mmol/L) [1] 
that results from defects in the body’s ability to produce and/or use insulin. It is estimated that 
347 million people suffer this chronic disease by 2011 [2] and the population with diabetes is 
continuing to increase. Diabetes remarkably increases the risk of cardiovascular events and 
death and many complications such as retinopathy, neuropathy and nephropathy [3]. There 
are two major types of diabetes, namely type 1 diabetes (also known as juvenile or insulin-
dependent diabetes) and type 2 diabetes (also known as adult-onset or non-insulin dependent 
diabetes). In the type 1 diabetes, little or no insulin that produced by β cell from pancreas 
stimulates glucose uptake into cells, resulting in an elevation of blood glucose. As the 
dysfunction of the β cell is due to the body’s own immune system [4], type 1 diabetes is 
mainly regarded as autoimmune diseases. In contrast, type 2 diabetes is the most common 
form of diabetes which comprises 90% of people with diabetes. Type 2 diabetes derives from 
insulin resistance that leads to high blood glucose levels (hyperglycemia) [5]. Under 
physiological condition, blood glucose level is maintained by the circulating insulin. However, 
when the body becomes insulin resistant, the insulin at normal level is no longer able to keep 
the blood glucose homeostasis. To compensate for this disorder, more insulin is released from 
the pancreas, leading to a high concentration of insulin in the plasma (hyperinsulinemia). As 
the β cell becomes exhausted, circulating insulin levels decrease. Consequently, the body 
develops glucose intolerance and hyperglycemia. Thus, oral drugs and/or insulin injection is 
applied to maintain blood glucose levels. Type 2 diabetes is commonly diagnosed in the aged 
population [6]. However, there is an increased population of diabetic patients in younger 
people, even children. A healthy lifestyle including regular physical activity, healthy food and 
losing excess body weight can decrease the risk of the development of type 2 diabetes [7]. 
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Diabetes is associated with a number of complications. These complications are wide ranging 
[8-11] and are due at least in part to chronic elevation of blood glucose levels, which leads to 
damage of blood vessels [12]. The complications resulting from the damage of blood vessels 
are termed as “microvascular disease”, including eye disease (retinopathy) [13], kidney 
disease (nephropathy) [14] and neural damage (neuropathy) [15]. This thesis focused on the 
early events in the development of type 2 diabetes particularly, insulin resistance.  
 
1.1.2 Insulin resistance 
1.1.2.1 Physiological role of insulin in fuel metabolism  
Insulin is a hormone secreted by pancreatic β cells and affects a wide range of physiological 
processes. Liver, muscle and adipose tissue are the three major tissues responsible for insulin 
action to regulate blood glucose level. High blood glucose levels after a meal promotes insulin 
secretion. After being taken up by the skeletal muscle and to a less extent by the liver, glucose 
is catalyzed to glycogen as energy storage, promoted by the insulin. At the same time, 
glycogenolysis and gluconeogenesis in the liver are suppressed. However, when glycogen 
levels in the liver are high, glycogen synthesize is suppressed. In this case, additional glucose 
taken up by liver cells is shunted into the synthesis of fatty acids, which are then transported 
from the liver into other tissues. Meanwhile, the rate of fatty acid oxidation is reduced. In the 
muscle, insulin increases the rate of glucose transport across the cell membrane, leading to 
enhanced glucose uptake from the bloodstream. Simultaneously, it stimulates the glycogen 
synthesize in the muscle to store glucose [16]. In adipose tissue, insulin stimulates the uptake 
of triglyceride from the blood and decreases lipolysis to maintain the plasma fatty acid level. 
Together with other hormones such as glucagon, insulin plays major roles in the regulation of 
Chapter 1 
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blood glucose concentration and overall flow of fuels. Insulin is also implicated in protein 
metabolism, cell growth and survival [17].  
 
Figure 1.1 The effects of insulin on glucose metabolism and lipid metabolism. 
Insulin is able to enhance glucose uptake and glycolysis in the muscle and adipose tissue. 
Besides these effects, insulin also enhances glycogen synthesize in the liver, muscle and 
adipose tissue. Glycogenolysis and gluconeogenesis in the liver are suppressed by insulin. 
Fatty acids and triglyceride synthesize in the liver and adipose tissue is upregulated by insulin 
as well as triglyceride uptake in the muscle and adipose tissue. VLDL formation and 
cholesterol synthesize can be elevated by insulin. Lipolysis in the adipose tissue and fatty 
acids oxidation in the liver and muscle are downregulated in response to insulin (L: liver; M: 
muscle; A: adipose tissue). 
 
1.1.2.2 Insulin signaling cascade 
The secretion of insulin is stimulated in response to increasing level of glucose, fatty acids 
or/and to a less extent of amino acids, in the bloodstream. Insulin binds to insulin receptors 
(IR) embedded in the plasma membrane [16]. The IR is composed of two α subunits and two 
β subunits. The α units are located in the outside membrane and house insulin binding 
domains, while the linked β units penetrate through the plasma membrane. The IR is a 
tyrosine kinase receptor such that the binding of insulin to its α units leads to the 
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autophosphorylation of β units at the tyrosine residues to activate the receptor [18, 19]. The 
activated IR then phosphorylates intracellular insulin receptor substrate (IRS), to provide a 
docking side to recruit phsphoinositide-3,4,5-trisphosphate (PIP3). IRS is recruited to the 
receptor at the cell membrane, and includes four isoforms: IRS1, IRS2, IRS3 and IRS4. IRS1 
serves as a docking center for recruitment and activation of downstream enzymes that 
ultimately mediate insulin effects. IRS2 serves as the primary protein to mediate the effect of 
insulin on hepatic glucose production, gluconeogenesis and glycogen formation in the liver 
[20]. The phosphorylation on tyrosine residues of IRS allows it to initiate downstream 
responses. However, there are other phosphorylation residues of IRS that are induced by other 
enzymes, and do not response to insulin. The negative regulation of insulin action will be 
discussed in the next section. Downstream of IRS, phosphatidylinositol-3-kinase (PI3K) is 
composed of an adaptor/regulatory subunit (p85) and a catalytic subunit (p110). The former 
interacts with activated IRS, leading to the induction of PI3K, while the latter catalyzes 
phosphatidylinositol-4, 5-bisphosphate (PIP2) to PIP3, a second messenger in the plasma 
membrane [21]. The increased PIP3 recruits a subset of signaling proteins with pleckstrin 
homology (PH) domains, including protein kinase B (PKB, or Akt) and phosphoinositide-
dependent kinase 1 (PDK1) [22]. PDK1 phosphorylates Akt at threonine (Thr) 308, leading to 
stabilization of the activation loop in an active conformation. The Ser473 phosphorylation of 
Akt that may be induced by protein kinase C α (PKCα), or by PDK2 [23]. Thr308 and ser473 
phosphorylations are required for the activation of Akt to induce diverse signaling cascades 
downstream [24].  
Activation of Akt leads to a range of cellular responses. The review here will focus on its role 
on glucose and lipid metabolism. The mechanism by which Akt might contribute to insulin-
mediated suppression of glycogenolysis in the liver as well as muscle is mainly by driving 
glycogen synthesize [16]. Glycogen synthase kinase-3 (GSK3) plays a negative role to link 
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Akt and glycogen synthesize. Phosphorylation of GSK3 dephosphorylates glycogen synthase 
to suppress glycogen synthesize [25, 26]. Thus, under physiological condition, GSK3 is 
inhibited in its phosphorylation form by activated Akt. In order to reduce blood glucose levels 
in response to insulin, Akt also stimulates glycolysis. It is suggested that Akt might indirectly 
induce the glycolysis rate-limiting enzyme, phosphofructokinase-1 (PFK1) by directly 
phosphorylating phosphofructokinase-2 (PFK2) [27]. Meanwhile, Akt also plays an important 
role in glucose transport in skeletal muscle and adipose tissue, by mediating the translocation 
of glucose transporter type 4 (GLUT4) [28]. In terms of its role in lipid metabolism, Akt is 
considered to link to the sterol-regulatory element binding proteins (SREBPs) which are 
transcription factors regulating lipid metabolism. The potential mechanisms by which Akt 
influences SREBPs could be through GSK3 by preventing the mature SREBP degradation 
[29]. Another possible mechanism is related to the mammalian target of rapamycin (mTOR). 
The effects of mTOR on modulating SREBPs cleavage is through Akt activation [30].  
 
Figure 1.2 Simplified insulin signaling cascade and its role in glucose and lipid metabolism. 
The details are described in 1.1.2.2. 
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1.1.2.3 Negative feedback control of insulin signaling transduction 
Control over insulin signaling pathways can be achieved by negative feedback from 
downstream components [31, 32]. Signals from other pathways can inhibit insulin signaling. 
However, the IRS proteins are also subject to the negative feedback control mechanisms. 
Phosphorylation of IRS proteins at serine residues is a key step in the feedback control 
processes [33, 34]. For example, the Ser/Thr phosphorylation of IRS proteins by PKCζ leads 
to the dissociation of IR: IRS [35] and IRS: PI3K [36] complexes. This dissociation then 
inhibits the ability of IRS to undergo further insulin-stimulated tyrosine (Tyr) phosphorylation. 
Desensitization of insulin signaling could also trigger by inflammatory signal. C-Jun NH2-
terminal kinase (JNK), which is mediated by stress, promotes the phosphorylation of Ser307. 
Ser318 of IRS1 is also a potential target for JNK, as well as PKCζ [37]. 
 
1.1.2.4 Insulin resistance 
Insulin resistance is the inability of the body to response to, and to use, insulin it produces and 
it is one of the major disorders of type 2 diabetes [38, 39]. Insulin action is defective in the 
liver, skeletal muscle and adipose tissue when there is insulin resistance [40]. Insulin 
resistance is also considered as a key link between type 2 diabetes and obesity [41]. In the 
pre-diabetic stage, blood glucose is maintained relatively normal due to a compensatory 
increase of insulin secretion while body already becomes insulin resistant [42]. However, 
prolonged insulin resistance could lead to β-cell failure and circulating insulin levels become 
insufficient to maintain blood glucose concentrations, resulting in hyperglycemia and the 
development of diabetes.  
Insulin resistance is a characteristic feature of glucose intolerance, involving both liver and 
skeletal muscle, in type 2 diabetic individuals [43]. Deficiency in insulin-stimulated glycogen 
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synthesize and increased gluconeogenesis in the liver are major characteristics of hepatic 
insulin resistance and fasting hyperglycemia [44]. Kraegen and colleagues performed 
hyperinsulinemic-euglycemic clamps in high fat fed mice and their results showed that the 
insulin resistance in muscle is a later occurrence than hepatic insulin resistance in the high fat 
fed rat [45]. Therefore, the present project will focus on hepatic insulin resistance which 
occurs prior to peripheral insulin resistance. 
 
 
Figure 1.3 Insulin resistance in different tissues.  
Under the insulin resistant state, insulin is unable to suppress glucose production by the liver 
and decrease glucose uptake in the muscle, which together lead to elevated blood glucose 
levels. Meanwhile, lipolysis in the adipose tissue increases, resulting in upregulation of 
plasma fatty acids levels [46]. 
 
1.2 Lipid metabolism 
Lipids are one of the major energy resources for the body. Adipose tissue has been considered 
as a major site for storage of extra fuel. After increased food intake and/or decreased energy 
expenditure, excess energy is deposited efficiently in adipose tissue [47, 48]. Abnormal lipid 
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metabolism leads to excess lipid accumulation in adipose tissue and other non-adipose tissues 
such as skeletal muscle and liver. These detrimental effects are important pathogeneses of 
metabolic disorders such as diabetes, obesity and fatty liver disease. More than 90% of the 
lipid is in the form of triglyceride. Triglycerides come from three primary sources: 1) 
absorption from the diet; 2) storage depots in adipocytes and 3) de novo synthesize (DNL) 
[49].  
Fat from diet is dissolved by bile salts that can cope with the insolubility of lipids and is 
transported through the blood and lymph partly by lipoproteins. Triglycerides are broken to a 
mixture of glycerol, free fatty acids, monoacylglycerols, and diacyglycerols by a lipase 
secreted from the pancreas. Triglyceride is resynthesized after absorption from the hydrolysis 
products and then transported to tissues with lipoproteins as the form of chylomicrons [50]. In 
current thesis, we focused on lipid synthesis (lipogenesis). Fatty acid oxidation will also be 
reviewed in this part. 
 
1.2.1 Lipogenesis 
1.2.1.1 Lipid synthesis 
DNL is the process of formation of lipids from non-fat precursors such as carbohydrates to 
fatty acids [51, 52]. Adipose tissue and liver are the major sites of DNL [53]. The first 
committed step of DNL is the formation of malonyl-CoA from bicarbonate and acetyl-CoA 
which is a central metabolite from either the pyruvate dehydrogenase reaction or fatty acid β-
oxidation, catalyzed by acetyl-CoA carboxylase (ACC). Malonyl-CoA is used mostly as a 
substrate by fatty acid synthase (FAS) for DNL. Fatty acid chain which contains successive 
additions of two carbon units needs to be built up from malonyl-CoA. In animals, all of the 
activities of adding carbon units are linked to a highly-structured multienzyme complex, FAS. 
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The resultant product, including mainly 16C palmitic acid and minor amounts of 18C stearic 
acid[54], are either elongated or desaturated. The elongation of fatty acid chains is essential 
for many membrane lipids. Unsaturated fatty acids are necessary for lipid storage, membrane 
synthesize and maintenance. Monounsaturated fatty acids are formed by direct oxidative 
desaturation with oxygenase type of enzyme that associated with the endoplasmic reticulum 
(ER) in the liver, mammary gland, brain, testes and adipose tissue. The stearoyl-CoA 
desaturase (SCD) is the predominant desaturation enzyme for saturated acids in these tissues 
and is rate-limiting in the formation of 18:1 n-9. There are two isoforms of SCD which are 
SCD1 that expresses exclusively in the liver whereas brain, spleen, heart and lymphocytes 
express only SCD2 [55]. 
Fatty acids, together with glycerol-3-phosphate, are resources of triglyceride that is mainly 
synthesized in the liver and adipose tissue [56]. Glycerol-3-phosphate is either from the 
reduction of the glycolytic intermediate dihydroxyacteone phosphate or from ATP-dependent 
phosphorylation of glycerol. Lysophosphatidic acid is the first product catalyzed by sn-1-
glycerol-3-phosphate acyltransferase (GPAT) from glycerol-3-phospate and acyl-CoA. It is 
further catalyzed by sn-1-acyl-glycerol-3-phosphate acyltransferase (AGPAT) to the 
formation of phosphatidic acid which is then metabolized to produce 1,2-diacyglycerol 
(DAG). DAG is further acylated by sn-1,2-diacylglycerol acyltransferase (DGAT) to form 
triglyceride [50].  
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Figure 1.4 Lipid synthesize pathway. 
The details are described in 1.2.1.1. 
Glucose-6-P: glucose-6-phosphate; Dihydroxyacetone-P: dihydroxyacetone-phosphate; 
Acetyl-CoA: Acetyl coenzyme A; Glycerol-3-P: glycerol-3-phosphate; ER: endoplasmic 
reticulum; ACC: Acetyl-CoA carboxylase; FAS: fatty acid synthesis; SCD: Stearoyl-CoA 
desaturase; Complex FAs: complex fatty acids. 
 
1.2.1.2 Regulation of lipogenesis 
Lipogenesis can be stimulated by a high carbohydrate diet via up-regulating the enzymes that 
are involved in triglyceride biosynthesize. Depending on insulin and glucose levels, this 
process can be regulated by specific transcription factors. SREBP1c [57] and carbohydrate 
response element binding protein (ChREBP) [58] are two critical transcription factors of 
lipogenesis.  
SREBP1c 
SREBPs are a family of transcription factors that regulate lipid synthesize by controlling a 
range of enzymes required for lipid metabolism. There are three isoforms of SREBP: 
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SREBP2, SREBP1a and SREBP1c, of which the last one is closely related to lipogenesis and 
expressed in most tissues in humans and mice, with especially high levels in the liver, white 
adipose tissue and brain [59]. SREBP1c is considered as a major transcriptional factor 
involved in the insulin regulation of lipogenic protein expressions [60]. SREBPs are 
synthesized as an inactive form in the ER membrane where they reside in a complex with 
SREBP-cleavage activating protein (SCAP) and the insulin-induced gene (Insig). When 
SCAP is activated by low sterol levels, it undergoes a conformational change and 
disassociates from Insig. The precursors of SREBPs are then transported to the Golgi 
apparatus with the assistance of SCAP to undergo proteolytic cleavage by site-1 protease (S1P) 
and site-2 protease (S2P) to release the N-terminal domain which constitutes the mature 
transcription factor [61, 62]. Once SREBPs in the nucleus are in the mature form, they are 
subject to a number of post-translational modifications that regulate the transcriptional 
activity of the active transcription factor [63]. Insulin is a potent activator of SREBP1c. The 
effect of insulin has been shown by in vivo studies. SREBP1c expression and nuclear 
abundance are low in the liver of diabetic animals and increase remarkably after an insulin 
treatment [64]. The effect of insulin on SREBP1c is mediated by a PI3K-dependent pathway 
[65]. However, the downstream mechanism is not clear. Another potent activator is liver X 
receptor (LXR). Although the LXR has been reported to play vital roles in regulating 
cholesterol metabolism, it has been identified to be able to target on SREBP1c [66]. The 
stimulation of LXR by its agonist increases gene and protein expression of SREBP1c [67]. 
Besides insulin and LXR, it is suggested that SREBP1c can be regulated by other effectors. 
Forkhead box protein 1 (FoxO1) is another regulator that can suppress SREBP1c 
transcriptional activity in HepG2 cells [68]. In addition, nutritional regulation of SREBP1c is 
demonstrated to be independent of insulin as long as sufficient carbohydrates are available 
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[69]. ER stress is also able to modify the expression of SREBP1c, which will be reviewed in 
1.6.1. 
The target enzymes of SREBP1c include ACC, FAS and SCD1, which are rate-limiting 
enzymes in lipogenesis. The down-regulation of SREBP1c leads to the reduction of 
lipogenesis. The inhibition of SREBP1c in high-fat diet induced obese mice resulted in a 
decrease in total plasma triglycerides and total liver fat. The inhibition of SREBP1c can also 
lead to a reduction of levels of lipogenic proteins such as ACC, FAS and SCD1[70]. Notably, 
hepatic SCD1, unlike the other two critical targets enzymes (ACC and FAS) of SREBP1c is 
proposed be upregulated by dietary carbohydrates in both SREBP1c-dependent and 
SREBP1c-independent pathways. The other regulator of this pathway other than SREBP1c is 
suggested to be the thyroid hormone [71].  
 
ChREBP  
ChREBP is a member of the basic helix-loop-helix/leucine zipper (bHLH/ZIP) family of 
transcription factors. It can be activated by high glucose and inhibited by cAMP [72]. Like 
SREBP1c, ChREBP is a key determinant of lipid synthesize as a glucose-responsive 
transcription factor in the liver [73]. ChREBP stays in the cytoplasm when the glucose 
concentration is low and moves into the nucleus when the glucose concentration is high [72]. 
Besides the regulation of its subcellular location by glucose concentrations, ChREBP is also 
regulated at post-translational level for its activities, e.g. via phosphorylation and 
dephosphorylation [74]. It is also likely that ChREBP activity is dependent secondarily on 
SREBP1c, because of activation of glucokinase by SREBP1c [63]. 
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The role of ChREBP in the regulation of lipid and glucose metabolism is complex. It has been 
reported that the liver-specific inhibition of ChREBP affected the rate-limiting enzymes in 
lipogenesis which are ACC, FAS and SCD1 [75]. ChREBP knockdown significantly restores 
insulin sensitivity in the liver, in agreement with the concept that excessive hepatic lipid 
accumulation leads to insulin resistance [76]. However, another study demonstrated that 
increased ChREBP can dissociated hepatic steatosis from insulin resistance, with beneficial 
effects on both lipid and glucose metabolism in a ChREBP overexpression model [77]. 
 
1.2.2 Fatty acids oxidation and lipid transportation 
Besides of lipid synthesize, fatty acids oxidation and transport also contribute to the lipid 
homeostasis as discussed here.  
 
1.2.2.1 Fatty acids oxidation 
Fatty acid oxidation is a major component of lipid metabolism. Liver and muscle are two 
major sites of fatty acid oxidation. Types of oxidation include: β-oxidation, α-oxidation, ω-
oxidation and peroxisomal-oxidation. β-oxidation in the mitochondria is the major mechanism 
of fatty acid oxidation [78]. It is the process of breaking down a long chain acyl-CoA to 
acetyl-CoA, via the sequential removal of 2-carbon units by oxidation at the β-carbon position 
of the acyl-CoA molecule. Each round of β-oxidation involves four steps, oxidation, 
hydration, oxidation and cleavage. The final products enter into TCA cycle, where they are 
further oxidized to CO2.  
The oxidation of fatty acids yields significantly more energy per carbon atom than does the 
oxidation of carbohydrates. The degradation of palmitoyl CoA (C16-acyl CoA) requires seven 
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reaction cycles. In the last cycle, the C4-ketoacyl CoA is thiolyzed to two molecules of acetyl 
CoA. The stoichiometry of oxidation of palmitoyl CoA is described in Table 1. The 
equivalent of 2 molecules of ATP are consumed in the activation of palmitate. Hence, the 
complete oxidation of a molecule of palmitate yields 106 molecules of ATP [79]. 
 
Table 1 Energy yields of palmitoyl CoA. 
C 16:0-CoA +7 FAD + 7 NAD+ +7H2O +7 CoA→8 Acetyl-CoA+7 FADH2+ 7 NADH + 7 
H+ 
7 NADH 17.5 ATP 
7 FADH2 10.5 ATP 
8 Acetyl-CoA 80 ATP 
 
For the complete oxidation of palmitic acid (16:0), seven β-oxidation cycles are required. 8 
Acetly-CoA are generated. 7 mol of FADH2 and 7 mol of NADH and H
+ are produced as well. 
Every 8 Acetyl-CoA generate 80 molecules of ATP while 7 FADH2 generate 17.5 molecules 
of ATP and 7NADH generate 10.5 molecules of ATP.  
 
1.2.2.2 Lipid transport 
Triglycerides are transported in body fluids in the form of lipoprotein particles [80]. 
Lipoproteins are responsible for carrying lipids via the bloodstream to other parts of the body 
[81]. Multiple enzymes and proteins are involved in the transport process. Dietary (exogenous) 
fat can be formed into large chylomicron particles in the Golgi complex of intestinal cells to 
other tissues such as liver. Assembly and secretion of chylomicrons is dependent of the 
present of apolipoprotein (apo) B. Liver is a major site of triglyceride synthesizes. Excessive 
endogenous triglycerides are assembled as the form of very low density lipoprotein (VLDL) 
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for export. In the liver, microsomal triglyceride transfer protein (MTTP) is involved in the 
formation of VLDL [82]. 
 
1.2.3 Other fates of intracellular lipids 
Besides oxidation, the majority of fatty acids are incorporated into glycerolipids [83]. The 
first committed step is the acylation of sn-glycerol-3-phophate to form lysophosphatidic acid 
catalyzed by GPAT. Subsequent lysophosphatidic acid (LPA) acylation results in the 
production of phosphatidic acid that is dephosphorylated to produce DAG. This reverses 
lipogenesis to form triglyceride (TG). 
Another fate of intracellular fatty acids is involvement in the biosynthesize of sphingolipids. 
Palmitoyl-CoA and serine are catalyzed by serine palmitoyltransferase (SPT) to produce 3-
oxoshpinganine. The following pathways result in the production of sphinganine, 
dihydroceramide and ultimately ceramide. Ceramide is the precursor of most active 
sphingolipids [83].  
 
1.3 ER stress and the unfolded protein response 
1.3.1 Endoplasmic reticulum 
The endoplasmic reticulum (ER) exists in all eukaryotic cells. The ER membrane forms a 
continuous sheet enclosing a single internal, convoluted space, called the ER lumen [81]. The 
ER plays an important role in lipid biosynthesize and is the site for producing phospholipids, 
cholesterol, triacylglycerol and ceramides. The ER is also a central coordinator of protein 
synthesize, folding and processing [84]. Another key function of ER in maintaining cellular 
homeostasis is as an intracellular Ca2+ storage site.  
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1.3.2 ER stress and the unfolded protein response (UPR) 
A number of pathological and physiological conditions can directly or indirectly disturb ER 
function and lead to ER stress. ER stress is triggered by excess unfolded or misfolded proteins 
accumulating in the ER lumen [85, 86]. For example, Ca2+ depletion has been reported to 
suppress protein folding, affecting retention of ER-resident proteins [87], ER-Golgi 
trafficking [88] and chaperone function [89]. Overload of protein and excess lipid 
accumulation are also suggested [78] to trigger ER stress. The mechanisms of how these two 
factors are involved in ER stress will be reviewed in 1.6.2. To deal with ER stress, cells 
develop an adaptive signaling pathway called the unfolded protein response (UPR). The 
physiological role of the UPR is to relieve ER stress by either increasing ER folding capacity 
or suppressing protein loading [90, 91]. However, under more severe conditions, UPR can 
interfere with the normal function of other pathways, and can even lead to cell apoptosis [91]. 
The UPR is mediated by three ER-resident transmembrane proteins that sense ER stress and 
mediate downstream signaling pathways. Under normal conditions, the three sensors bind ER 
chaperones, such as glucose-regulated protein 78 (GRP78) and glucose-regulated protein 94 
(GRP94) [92]. However, due to increased protein loading, the ER chaperones are moved to 
deal with misfolded or unfolded proteins [93, 94]. The release of the chaperones from their 
bound complexes activates sensors known as inositol-requiring protein 1 (IRE1), PKP-like 
endoplasmic reticulum kinase (PERK), and activating transcription factor 6 (ATF6). The 
activation of these signals may not occur simultaneously. For example, it has been reported 
that PERK is the first sensor to be activated once released from GRP78, and is rapidly 
followed by ATF6, whereas IRE1 is activated last[95]. Activation of these three sensors leads 
to activation of downstream signalling pathways such as chaperone synthesis, lipid synthesis 
and apoptosis. 
 
Chapter 1 
18 
 
1.3.2.1 IRE1 branch of the UPR 
IRE1 branch is the oldest branch of the UPR in an evolutionary sense and is conserved from 
yeast to humans [96]. The yeast UPR is entirely dependent on ER-resident, transmembrane 
endoribonuclease Ire1p [97]. In the mammal, IRE1 includes two subunits, IRE1α and IRE1β 
[98]. IRE1α is suggested to play a role in ER stress-induced hepatic steatosis [99] while 
IRE1β may play a role in lipid metabolism, especially in intestinal cells [100]. IRE1 consists 
of an N-terminal domain, a single-pass transmembrane spanning segment, a cytosolic region 
subdivided into a Ser/Thr protein kinase domain, and a C-terminal endoribonuclease domain 
[101]. After dissociation from its chaperones, the luminal domain of IRE1 dimerizes, allowing 
associated cytoplasmic domains to be close to the other side of the ER membrane. This 
change facilitates transautophosphorylation of the kinase domain, which results in activation 
of the endoribonuclease domain [102, 103]. The kinase activity of IRE1α can activate JNK in 
response to ER stress by interacting with the adaptor protein tumour necrosis factor (TNF) 
receptor-associated factor 2 (TRAF2) [104]. The endoribonuclease activity of IRE1α cleaves 
a 26-base fragment from mRNA encoding X-binding protein 1 (XBP1), leading to its spliced 
form sXBP1, and its subsequent translocation to the nucleus. Active sXBP1 can be regulated 
by ATF6 and is intimately associated with the ATF-controlled ER stress-response element 
(ERSE) [105, 106]. In addition, spliced XBP1 upregulates a number of UPR target genes that 
are related to protein folding, ER-associated protein degradation (ERAD) and protein quality 
control [107] . Moreover, IRE1α may regulate apoptosis by cleaving premature microRNAs 
[108]. IREβ, in turn, may directly bind misfolded proteins, similarly to yeast IRE1 [109].  
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1.3.2.2 PERK branch of the UPR 
The activation of PERK is similar to IRE1α and it involves dimerization and 
autophosphorylation and the formation of large clusters [110].  
Activation of the PERK pathway attenuates general protein synthesize by phosphorylation of 
eukaryotic translation initiator factor 2α (eIF2α). EIF2α activation is able to suppress protein 
synthesize, to decrease the number of proteins then entering the ER [107, 111]. Therefore 
PERK activation has an important pro-survival effect on the cell. The eIF2α phosphorylation 
also leads to the selective translation of the ATF4 mRNA. ATF4 regulates the expression of 
genes that encode proteins related to amino acid metabolism and ER chaperones [112]. ATF4 
also controls the expression of genes involved in apoptosis, including the transcription factor 
C/EBP-homologous protein (CHOP) and GADD34 [107].  
 
1.3.2.3 ATF6 branch of the UPR 
The activation of ATF6 is different from the other two branches of UPR. Similarly to 
SREBP1c, ATF6 is an ER membrane-bound transcription factor, and its activation is 
dependent on cleavage. The proteases that respond to this cleavage are the same as SREBP1c 
[113]. During ER stress, ATF6 translocates to the Golgi complex where it is processed to 
release a fragment to the cytoplasm. The cytosolic p50 fragment is the active form of ATF6, 
which then relocates to the nucleus where it regulates the expression of gene products [114]. 
The ATF6 branch of the UPR is reported to contribute to protein folding, protein secretion 
and ERAD, thereby supporting the cell’s effort to cope with ER stress and excessive 
misfolded/unfolded proteins [115, 116].   
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Figure 1.5 The unfolded protein response (UPR).  
In UPR, three ER membrane transducers are activated by release from GRP78 (BIP) binding. IRE1 is a ribonuclease that splices and religates XBP1 
transcripts for the synthesize of active transcription factor. Spliced XBP1 exerts the induction of expression of genes that relate to chaperone and lipid 
synthesize in the nuclear. PERK is a kinase that phosphorylates eIF2α and suppresses protein synthesize. ATF6 is a transcription factor that once 
released from ER will travel to the Golgi, cleaved and translocated to the nucleus,  to activate the transcription of chaperone genes (Adapted from 
Schonthal, A. H., Scientifica (Cairo) 2012).  
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1.4 Role of inflammation  
Inflammation is the first response to infection or irritation of the immune system, after 
referred to as the innate cascade. It has been implicated in the pathogeneses of arthritis, cancer 
and stroke, as well as in cardiovascular disease. Inflammation is an intrinsically beneficial 
event that induces the remove of detrimental factors and restoration of tissue structure and 
physiological function [117].  
 
1.4.1 Inflammation and insulin resistance 
The clues to the involvement of inflammation in diabetes were indicated more than a century 
ago. However the role of inflammation in the pathogenesis of insulin resistance was not well 
studied until late of 20th century and the early 21st century, by re-examining the hypoglycemic 
actions of salicylates and confirming that the molecular target was the IκB kinase-β (IKKβ)/ 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) axis [118, 119]. After 
the study of the induction of insulin resistance by TNFα, the concept of lipid as a site for 
cytokine production and other bioactive substances quickly extended to include leptin, IL-6, 
resistin and others [120].  
 
1.4.2 Inflammation in the liver 
Non-alcoholic fatty liver disease (NAFLD) is often associated with the presence of abdominal 
adiposity and its prevalence is increasing and related with T2D and hyperlipidaemia. 
Inflammation clearly plays a role in the progression of NAFLD. Inflammation gene 
expression shows increasing in the liver with enhanced adiposity [121]. This indicates that 
hepatic steatosis might induce a subacute inflammatory response in the liver. It is suggested 
that proinflammatory factors in the portal circulation might initiate hepatic inflammation. 
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Regardless, NF-κB can be activated in the hepatocyte. Cytokines including IL-6, TNFα and 
IL-1β are overexpressed in fatty liver [122]. 
 
1.4.3 Inflammation and ER stress 
Besides nutritional excess, and the related metabolic factors triggered by both metabolic 
dysfunction and inflammation, ER stress has been suggested to be activated and to mediate 
both metabolic and immune responses [103]. ER is the place where the majoring of proteins 
are processed, and the role of the ER tends to be particularly vital in immune cells as they 
produce a very large amount of protein. Communication governed by ER stress usually results 
in inflammation, to control tissue damage and aid in tissue repair [123].  
Following ER stress, the cytosolic domain of IRE1α can bind to TRAF2. The IRE1-TRAF2 
complex then activates IKK and consequently leads to IκB degradation to release NF-κB, to 
induce the proinflammatory process [104] [124]. In addition, the IRE1-TRAF2 complex may 
also activate JNK and this activation can be induced independently of XBP1 splicing [125]. 
Activated JNK then phosphorylates and activates AP-1, which induces its own inflammatory 
gene program [126]. PERK-activated eIF2α results in translational arrest, which leads to 
decreased content of IκB protein and consequently increases the ratio of NF-κB to IκB. This 
change causes the release of NF-κB which exerts the proinflammatory transcriptional role in 
the nucleus [127]. While inducing CHOP, PERK may also activate transcription of interleukin 
23(IL-23), a proinflammatory cytokine [128]. CHOP activation is suggested to negatively 
regulate the inflammatory response by activating both NF-κB and JNK. By contrast, ATF6, 
which leaves the ER to relocate to Golgi complex under ER stress, can lead to the acute-phase 
response (APR). APR is a group of organism-level physiological processes that are initiated 
soon after an inflammatory insult, trauma, or infection [103] [129]. 
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Figure 1.6 The URP-mediated inflammatory transcriptional program.  
The details are described in 1.4.3 (Adapted from Garg, A. D, et al., Trends Mol Med, 2012). 
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1.5 Relationship between lipid accumulation, UPR and insulin resistance 
Understanding the molecular mechanisms of insulin resistance is a major medical challenge in 
the 21st century. Over the last half-century, many hypotheses have been proposed to interpret 
insulin resistance. Since the early 1980s, excess lipid content and improper lipid location have 
been considered to be associated with insulin resistance [130]. As reviewed in 1.4.1, a chronic 
low degree of inflammation has been revealed to play a role in insulin resistance in liver, 
muscle and adipose tissues. During the last decade, a number of studies have pointed to an 
important role of ER stress/UPR in the development of insulin resistance [131, 132]. A 
number of studies have suggested a link between obesity, ER stress, insulin resistance and 
type 2 diabetes. These mechanisms have largely been explored in isolation, resulting in 
competing reductionist and compartmentalized proposals. Here we review current 
understanding of the complex relationships between lipid metabolism, UPR and insulin 
resistance are complicated.  
 
1.5.1 Lipid accumulation and insulin resistance 
The liver and skeletal muscle is the two major organs responsible for insulin action to 
maintain normal blood glucose levels. The livers of obese insulin resistant individuals are 
characterized by severe hepatic insulin resistance, which significantly contributes to 
hyperglycemia. However, insulin-dependent lipogenesis is paradoxically active. SBPRE1c 
levels in the liver are over-induced in ob/ob animals [133, 134]. The failure of insulin to 
suppress gluconeogenesis while lipogenesis is strongly stimulated could reflect a selective 
insulin resistance. A considerable number of studies have shown the detrimental effects of 
excess lipid level in insulin resistance [83, 135, 136]. In rats, high-fat feeding remarkably 
enhances hepatic DAG and TG content, without alteration in muscle lipid content [130]. 
Although there was no effect of fat feeding on insulin receptor tyrosine phosphorylation, 
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insulin-stimulated IRS1 and IRS2 tyrosine phosphorylation was blocked in these animals. 
Consistently, the downstream insulin effectors, Akt2 and GSK3 were suppressed. 
Interestingly, the blunted insulin signaling was observed only in liver, not in peripheral tissues 
[130]. The results suggest a link between hepatic steatosis and hepatic insulin resistance. 
However, the changes of lipogenesis transcriptional factors did not show detrimental effect on 
insulin signaling. Overexpression of ChREBP in mice fed a high-fat diet presented normal 
insulin levels, improved insulin signaling and glucose tolerance compared with controls, 
despite greater hepatic steatosis [77]. The absence of SREBP1c in leptin deficient mice 
ameliorated fatty liver but not insulin resistance [137]. The results from these studies 
demonstrate that hepatic steatosis could disassociate from hepatic insulin resistance under 
certain conditions. However, the excessive lipid accumulation remains a key factor in the 
development of insulin resistance.  
 
1.5.1.1 Diacyglycerol (DAG) 
DAG is an intermediate in lipid metabolism and an important second messenger in controlling 
cell division. The most common pathological cause of high intracellular DAG content in the 
liver is overnutrition [43]. Rats fed a high-fat diet exhibited high hepatic DAG content, which 
is associated with protein kinase C ε (PKCε) activity and decreased IRS tyrosine 
phosphorylation [130]. PKCε, a novel isoform of the protein kinase C family, is thought to 
play key roles in fat-induced hepatic insulin resistance. When DAG is present in sufficient 
concentrations, it binds to the C1 domain of PKCε and recruits PKCε from the cytosol to 
membrane to be activated [138]. Activated PKCε further leads to IRS serine phosphorylation 
to inhibit insulin signal transduction. PKCε-specific antisense oligionucleotide-treated rats are 
protected from fat-induced hepatic insulin resistance, despite similar levels of hepatic DAG 
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and TG levels [139]. Inhibition of hepatic DAG synthesizes by knocking out the gene 
encoding mitochondrial glycerol-3-phosphate acyltransferase protects mice from fat-induced 
hepatic insulin resistance [140]. In addition, enhanced fatty acid oxidation and mitochondrial 
uncoupling by knockdown of ACC, or the use of 2,4-dinitrophenol, reduces DAG content, 
consequently decreasing PKCε activation and protection from fat-induced hepatic insulin 
resistance [141]. A similar mechanism of DAG induced insulin resistance operates in the 
skeletal muscle. PKCθ activation in the muscle, rather than PKCε, could decrease IRS1-
associated PI3K activity to block insulin signal transduction [43]. 
 
1.5.1.2 Ceramides 
As mentioned in 1.2.3, ceramide is the precursor of sphingolipid, where synthesize is largely 
dependent on de novo biosynthesize. The rate of ceramide synthesize is predominantly 
dependent upon the availability of palmitate (16:0) CoA, which participate in the initial, rate-
limiting step in de novo ceramide synthesize [142]. The first analysis of ceramide levels in 
insulin resistance animals was performed prior to the observation that ceramide was a potent 
antagonist of insulin signaling [143]. Several subsequent studies have evaluated the increasing 
level of ceramides in muscle or liver of insulin resistant rodents [144] or humans [145]. It has 
been demonstrated that ceramide is able to block activation of Akt, a serine/threonine kinase 
that is required for insulin and factor activation of anabolism and cell survival [146]. This 
regulation is accomplished by at least two mechanisms. First, ceramide inhibits translocation 
of Akt from the cytoplasm to the plasma membrane [147]. The key intermediate is PKCζ, 
which is activated by ceramide in vitro [148]. PKCζ inhibits Akt translocation by 
phosphorylating threonine-34 [149]. The second mechanism involves the dephosphorylation 
of Akt by protein phosphatase 2A (PP2A) [150, 151]. Ceramides have been indicated to 
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directly activate PP2A, the primary phosphatase responsible for dephosphorylation of Akt. 
This has been demonstrated  in C2C12 myotubes [152], PC12 cells [153], brown adipocytes 
[150] or a human glioblastoma cell line [151], using a PP2A inhibitor. 
 
1.5.2 The UPR and insulin resistance 
In the past decade, UPR triggered by ER stress has emerged as a new player in type 2 diabetes, 
due to its detrimental effects on β-cells in the pancreas [154] and insulin action in the liver 
[155]. A number of studies have demonstrated the role of UPR in the progression of insulin 
resistance because it can transduce some effects of lipid metabolites and cytokines into an 
activation of these stress sensors. In addition, UPR has been proved to modulate key pathways 
including lipogenesis and gluconeogenesis [156]. It is commonly thought that UPR could 
contribute to the development of insulin resistance in the liver in three different ways: (i) 
transcription factors activated by UPR can directly modify transcription of critical lipogenic 
and gluconeogenic enzymes to lead to abnormal activation of these pathways under insulin 
resistance conditions [157-160], (ii) activation of UPR by stimulating stress kinases that 
interfere with insulin signaling can directly promote insulin resistance [161], and (iii) UPR 
may contribute to insulin resistance by promoting lipid accumulation in hepatocytes [131, 158, 
160].  
 
1.5.2.1 IRE1 branch and insulin resistance 
IRE1 activation upon ER stress induces JNK and IKK, of which both can impair insulin 
signaling by phosphorylation of IRS1 on serine 307 residues, as described above. Shulman’s 
group showed that IRE1-mediated JNK activation can be independent of hepatic insulin 
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resistance in XBP1 knockout mice fed a fructose diet [162]. This study hypothesised that the 
hepatic insulin resistance in models of ER stress could be secondary to lipid accumulation 
triggered by ER stress activated lipogenesis. JNK could be activated by different pathways, 
not always involving ER stress. In addition to IRE1 phosphorylation, ER stress can also 
activate JNK via calcium/calmodulin-dependent protein kinase II (CaMK II) [163].  
XBP1, a downstream effector of IRE1, is thought to stimulate hepatic lipogenesis, either 
dependently or independently of SREBP1c [158, 160]. XBP1 knockout mice exhibit reduced 
lipogenesis with decreased serum levels of triglycerides, cholesterol and free fatty acids [160]. 
Intriguingly, XBP1 splicing can be stimulated by insulin. Insulin increases the nuclear 
concentration of spliced XBP1 by promoting its binding to the p85 regulatory subunit of PI3 
kinase [164].  
 
1.5.2.2 PERK branch and insulin resistance 
Activated PERK is able to phosphorylate NF-E2-related factor 2 (NRF2), involved in the 
transcriptional regulation of lipogenic gene expression. Deletion of NRF2 in mice leads to 
reduced hepatic triglyceride levels and downregulation of genes involved in lipid synthesize 
and uptake [165]. NRF2 regulates lipid metabolism in the liver, either by upregulating the 
transcription of lipogenic enzymes such as FAS, SBPRE1c and SCD1, or by inducing the 
expression of small heterodimer protein (SHP) indirectly. Tribbles homolog 3 (TRB3) is 
involved in apoptosis and has been suggested to be involved in insulin resistance in obese 
subjects [166]. Knockdown of hepatic TRB3 improves glucose tolerance, whereas its 
overexpression leads to insulin resistance [167]. It has been demonstrated that TRB3 inhibits 
the insulin-induced activation of Akt. TRB3 has been considered as an ER stress-induced 
protein which is induced by ATF4 and CHOP by PERK branch [168]. Studies by Cohen’s 
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group indicated that the activation of PERK as a conserve signaling mechanism may have 
negative effects on insulin responsiveness at the level of FoxO activity. They demonstrated 
that PERK can act directly on FoxO to increase FoxO activity in human cells. The active 
FoxO subsequently suppress hepatic glucose production [169]. 
 
1.5.2.3 ATF6 branch and insulin resistance 
It has been suggested that overexpression of ATF6 is able to restore insulin-stimulated insulin 
receptor phosphorylation [170]. HEK293 cells treated with tunicamycin to induce ER stress 
and were then transfected with ATF6. Insulin receptor tyrosine phosphorylation was 
attenuated by tunicamycin, whereas overexpression of AFT6 protected against insulin 
resistance as a result of tunicamycin treatment [170]. Intriguingly, Hisamitsu’s group [171] 
observed that ATF6 contributes to both prevention and promotion of diabetes in mice. In their 
study, ATF6α knockout mice displayed higher insulin sensitivity, but lower pancreatic insulin 
content, in response to high fat-feeding.  
 
1.6 Lipid metabolism and ER stress 
1.6.1 ER stress induced lipid synthesize 
It has been shown that ER stress/UPR activation plays a crucial role in lipid metabolism and 
homeostasis [160, 172, 173]. Here, it is likely that ER stress-dependent dysregulation of lipid 
metabolism may result in dyslipidemia, insulin resistance, type 2 diabetes, and obesity. ER 
stress has been observed in several tissues from obese mice [125, 174] and humans [175, 176]. 
ER stress-induced UPR activation may also be relevant to fatty liver disease, where lipid 
droplets accumulate in the liver cells. The mechanisms by which UPR pathways mediate the 
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development of fatty liver disease has been under intense investigation. Werstuck and 
colleagues demonstrated that ER stress induced by homocysteine promotes hepatic steatosis, 
and triglyceride biosynthesize, both in vitro and in the livers of hyperhomocysteinemic mice 
[177]. Overexpression of GRP78, which improves ER stress and inhibits UPR activation, has 
been shown to alleviate hepatic steatosis by reducing SREBP1c activity [157].  
The IRE1 branch of ER stress has been shown to play a critical role in lipid metabolism. 
Zhang and colleagues [99] generated hepatocyte-specific Ire1α –null mice to elucidate the 
physiological roles of IRE1α-mediated signaling in the liver. They demonstrated that 
hepatocyte-specific Ire1α deletion increased hepatic lipid and reduced plasma lipid content 
upon ER stress. In addition, IRE1α was indicated to suppress expression of lipogenic 
transcriptional activators, including PPARγ, LXR and ChREBP. When treated with 
tunicamycin, hepatocyte-specific Ire1α –null mice exhibited a deficient adaption to ER stress 
and modified lipid metabolism in the absence of the IRE1α. Moreover, ATF4 and CHOP, 
downstream proteins of the PERK pathway were increased in tunicamycin treated hepatocyte-
specific Ire1α –null mouse liver [99]. However, another study in the same knockout mice fed  
a high fructose diet for 12 weeks did not show altered DNL, as indicated by unchanged 
expression of lipogenic enzymes (i.e. SCD1, FASN and ACC) and hepatic fatty acid 
synthesize as shown by labelling with [178] acetic acids [179].  
XBP1, the downstream effector of IRE1, is reported as sufficient to induce phospholipid 
biosynthesize and ER expansion in mammalian cells [180]. The regulation of phospholipid 
synthesize is dependent on the cellular needs for ER membrane components. The most 
definitive study of the critical role of XBP1 in hepatic lipid regulation comes from Lee’s 
group [160]. In this study, deletion of hepatic XBP1 led to lower lipid levels in the liver and 
reduced the expression of lipogenic genes such as DGAT2, SCD1 and ACC. XBP1 
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deficiencies led to profound compromise of de novo hepatic lipid synthesize, resulting in 
concomitant decreases in serum triglycerides and free fatty acids, in the absence of hepatic 
steatosis in high fructose feeding. Interestingly, IRE1α was activated in XBP1-deficient 
mouse liver, whereas the ATF6 processing, Bip and CHOP was absence [160]. In another 
study, IRE1α expression in the liver was silenced using siRNA in XBP1-deficient mice. 
IRE1α siRNA led to increased plasma triglyceride and cholesterol content in XBP1 knockout 
mice, suggesting that hyper-activated IRE1α contributes to the reduction of plasma lipids in 
the absence of XBP1 [179]. Furthermore, it has been demonstrated that XBP1 deficiency 
results in a feedback activation of IRE1α, inducing the degradation of mRNAs of a group of 
lipid metabolism genes (Dgat2, Acacb, Pcsk9, Angptl3 and Ces1) which regulate triglyceride 
and cholesterol metabolism at multiple levels [179]. 
In summary, the IRE1/XBP1 branch of UPR can regulate hepatic lipid metabolism via two 
distinct mechanisms. 1) IRE1α promotes the degradation of mRNAs encoding lipid 
metabolism genes involved in DNL, hydrolysis of triglyceride and lipoprotein catabolism. 2) 
IRE1α activates the XBP1 splicing, which can directly activate certain lipid metabolism genes.  
The eIF2α is a downstream target of PERK, involving in UPR signaling pathways. The 
attenuation of eIF2α by overexpression of GADD34 in the liver results in impaired glucose 
tolerance and diminished hepatosteatosis in animals fed a high-fat diet. This attenuation 
correlated with levels of PPARγ, an adipogenic nuclear receptor, and the transcription factor 
C/EBP [181]. 
CHOP plays an important role in ER stress-induced apoptosis, and has been suggested to 
suppress the genes involved in lipid homeostasis, likely by negatively affecting C/EBP [173]. 
ATF6 and SREBPs are ER membrane bound transcription factors that share the same 
proteases for cleavage by the Golgi [182]. A close investigation of the relationship between 
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ATF6 activity and SREBP2-mediated lipogenesis suggested that nuclear ATF6 interferes with 
the mature form of SREBP2 in the nucleus and therefore antagonizes SREBP2-regulated 
transcription of lipogenic genes and lipid accumulation in cultured hepatocytes [183]. 
Additional studies have also examined the role of ATF6 on liver disease and lipid droplet 
formation in vivo [173, 184]. ATF6 knockout mice presented no apparent phenotype under 
physiological conditions, however when challenged with an ER stress insult by injection of 
tunicamycin, the livers of knockout mice failed to recover [184, 185]. The phenotypic 
outcome of the ER stress insult in ATF6 knockout mice was hepatic steatosis, caused by 
induction of lipid droplet formation due to the reduced β-oxidation of fatty acids and 
suppressed VLDL formation [185]. 
 
1.6.2 ER stress induced by lipids 
Excess lipid accumulation and protein overload are two triggers of ER stress. Under 
physiological conditions, one of the roles of lipids on ER function is to maintain the ER 
capacity as phospholipids are an important component of the ER membrane. The composition 
of lipid affects many membrane-associated functions. Saturated fatty acid has been 
demonstrated to be a detrimental lipid in ER stress in cultured cells [186, 187]. It has been 
reported in contrast that unsaturated fatty acids led to a reduction of palmitate-induced 
upregulation of GRP78, GADD34 and CHOP in cultured cells. It has also been reported that 
hepatic steatosis caused by saturated fatty acid-enriched diets is associated with ER stress and 
liver injury, despite similar accumulation of triglycerides [188]. The negative effect of 
saturated fatty acids in ER stress was confirmed using SCD1-deficiency. Knockdown of 
SCD1 expression caused increased saturation of fatty acids and induced UPR [189]. Increased 
saturated fatty acids in the blood are also linked to insulin resistance and the risk of diabetes 
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in humans [190-192]. This phenomenon was also demonstrated in animal models, where 
treatment of animals with palmitate, a saturated fatty acid, induced acute ER stress and 
cytotoxicity [172]. These indicate a potential correlation between ER stress and insulin 
resistance. In addition, exposure to excess fatty acids over long periods of time may lead to 
overload, especially of nonadipose cells, resulting in chronic ER stress and lipotoxicity, as 
demonstrated in cell culture. When cells were incubated with oleic acid for a short time, both 
VLDL and triglyceride secretion were increased, while extended incubation led to ER stress 
and suppression of VLDL secretion [188]. This disorder of ER stress and suppression can be 
restored both in vivo and in vitro by 4-phenylbutyrate (PBA), a chemical chaperone, 
indicating that the chronic effects of fatty acids on ER function are related to compromised 
chaperone function [188]. Moreover, other studies have observed a chronic state of ER stress 
in obese subjects, in both mice or humans [156], which has allowed researchers to presume 
that the mechanism relates, at least in part, to a long term exposure to lipids. 
Overload of proteins, the same as excessive lipid, is an endogenous trigger of ER stress. 
Another study from our group suggested that ER stress is involved in DNL per se rather than 
resulting from steatosis in the liver and insulin resistance, by comparing the HFru and HFat 
diets [193]. Studies by Hotamisligil’s group [194] found that during ER stress in ob/ob mice, 
although ER-associated protein synthesize was suppressed in the liver, an augmention was 
detected of genes involved in DNL. When phosphatidylethanolamine N-methyltransferase 
(Pemt), responsible for phospholipid synthesize was suppressed, ER stress was an improved. 
However, in addition to the reduction of lipid content, a remarkable decrease in lipogenic 
genes was also detected.  Whether or not increasing pecific proteins in lipogenesis are able to 
initiate ER stress, is not yet clear.  
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1.7 PPARα and lipid metabolism 
PPARα belongs to the family of peroxisome proliferator-activated receptors (PPARs). 
Transcriptional regulation of PPARα is achieved by direct binding to specific nucleotidic 
sequences, in the promoter region of target genes or in an intronic sequence of a gene [195-
197], such as PPARα can be activated by both endogenous and synthetic ligands. The 
increased fatty acid influx into the cell resulting from fasting or high fat feeding is able to 
activate PPARα [198, 199]. PPARα is also a molecular target for fibrates. Fenofibrate is a 
derivative of a fibric acid used for the treatment of mixed dyslipidaemia and hyper-
triglyceridaemia in adults [200]. These effects are mediated by the activation of PPARα. 
PPARα activation induces the expression of multiple genes involved in lipid metabolism, 
including both fatty acid oxidation and other lipid metabolic processes [201, 202]. The first 
report of the relationship between PPARα and fatty acid oxidation was published in 1992 
[203]. The authors reported that activation of PPARα upregulates the expression of 
peroxisomal acyl-CoA oxidase, a key enzyme involved in peroxisomal fatty acid β-oxidation. 
Further studies have demonstrated that the mitochondria fatty acid β-oxidation is also 
regulated by PPARα as well as peroxisomal fatty acid β-oxidation [201].  
Although most of the PPARα target genes are involved in fatty acid catabolism, some genes 
involved in lipogenesis has also been identified as PPARα targets [204-206]. The malate 
NADP oxidoreductase catalyzes the oxidative decarboxylation of malate into pyruvate, 
generating the energy required for fatty acid synthesize. PPARα knockout mice show 
decreased malate NADP oxidoreductase in the liver, indicating a potential link with PPARα 
[204]. In addition, SCD1 is a direct target gene of PPARα, as it catalyzes saturated fatty acids 
to unsaturated fatty acids [205]. Other desaturases have also been found to be upregulated by 
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PPARα [206]. These findings suggest that PPARα may play an important role in the 
conversion of saturated fatty acids to unsaturated fatty acids. 
Regulation of PPARα can be complex in physiological conditions. For example, PPARα-
mediated upregulation of some desaturases may serve to counteract excess fatty acid 
breakdown caused by the induction of oxidation [207]. Alternatively, the induction of 
desaturases serves to provide endogenous ligands for PPARs, as unsaturated fatty acids may 
be better PPARα ligands [208]. It has also been suggested that PPARα and SREBP1regulate 
desaturases, where SREBP1 is responsible for feeding periods, and PPARα exerts regulation 
during fasting [207].  
While several pharmacological agents are commonly used as PPARα specific agonists, 
including WY14643 [209] and GW7647 [210], only fibrates (often fenofibrate) are used 
clinically to treat dyslipidemia. Fenofibrate is a fibric acid derivative and is a pharmacological 
PPARα agonist that is used clinically to treat dyslipidemia. In primary dyslipidemia, 
fenofibrate monotherapy consistently reduced triglyceride content, significantly increased 
high density lipoprotein cholesterol levels while suppressed the low-density lipoprotein 
cholesterol and total cholesterol levels [200].  
 
1.8 Tauroursodeoxycholic acid 
Tauroursodeoxycholic acid (TUDCA) is an ambiphilic bile acid. It is the taurine conjugate 
form of ursodeoxycholic acid (UDCA) [211]. TUDCA has been safely used as a 
hepatoprotective agent in humans with cholestatic liver diseases; it ameliorates ER stress in 
cells and whole animals by blocking calcium-mediated apoptotic pathways [212]. It is also a 
chemical chaperone that can modulate ER function by protecting against UPR induction and 
ER-stress induced apoptosis [213]. Consequently, TUDCA is often used to attenuate ER 
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stress in animal studies. When treated with TUDCA, obese mice present reduced expression 
of UPR transducers such as p-PERK and p-IRE1. IRSser307, which can be activated by JNK, 
also decreased as did JNK itself in TUDCA treated animals. Moreover, blunted insulin signal 
transduction was observed [212, 214].  
 
1.9 Role of dietary fructose  
1.9.1 Fructose consumption 
There is a dramatic increase in dietary sugar consumption in the world over the past four 
decades. The increased consumption is paralleled by epidemics in obesity and metabolic 
syndrome, suggesting a causal relationship [215]. A character of most Western diets is the 
utilization of high levels of carbohydrate, especially sugar [216]. A growing body of evidence 
demonstrates that in addition to overall sugar intake, fructose is especially harmful to 
metabolic health as a risk factor for obesity and type 2 diabetes [217-221]. The rapid increase 
in fructose consumption is mainly due to the use of high fructose corn syrup (HFCS) in food 
and beverage production, as a sweetener. The typical form of HFCS-55 has 10% more 
fructose than sucrose [222]. It has been reported that countries with HFCS as a second 
sweetener exhibit an elevated risk of diabetes beyond the effects of sugar itself and of BMI, 
possibly due to its higher content of fructose (Table 2) [222]. One study in healthy subjects 
shows a significant increase in fasting blood glucose level after ingestion of 20% fructose 
solution as part of the three main daily meals for the 6 days before the test [223]. These 
subjects developed insulin resistance in the liver and adipose tissue, but not in muscle, when 
assessed by hyperinsulinemic-euglycemic clamp combined with the use of 3H-glucose [223, 
224]. Only fructose consumption led to a significant increase in hepatic de novo lipogenesis in 
Chapter 1  
 
37 
 
overweight and obese subjects who consumed either glucose- or fructose-sweetened 
beverages for 10 weeks. Moreover, fasting blood glucose and insulin levels were upregulated, 
while insulin sensitivity was downregulated in the subjects consuming fructose, but not in 
those consuming glucose [225]. These indicators of diabetes were higher in countries that use 
HFCS as compared to those that do not, and this trend was significant for International 
Diabetes Federation estimates of diabetes prevalence and fasting plasma glucose [222]. 
Table 2 Comparison of countries with low vs. high availability of HFCS. 
  
Countries not 
using HFSC 
(n=22) 
Countries using 
HFSC (n=21) 
p-Value 
Prevalence of Diabetes (IDF) (%) 6.3±1.5 7.8±2.1 0.013 
Fasting glucose (mmol) 5.23±0.17 5.33±0.17 0.046 
BMI (kg/m2) 25.5±1.6 25.9±1.4 NS 
Total intake (Kcal/day per capita) 3230±377 3221±365 NS 
Cereals (kg/year per capita) 129.8±30.1 137.0±36.2 NS 
Total sugar (kg/year per capita) 38.2±12.8 39.9±11.3 NS 
Other sweeteners (kg/year per capita) 5.5±7.1 6.1±8.3 NS 
 
IDF: International Diabetes Federation.  
(Adapted from Goran, M. I., et al. Glob Public Health, 2013) 
 
1.9.2 Fructose metabolism 
Although fructose has the same molecular formula and molecular weight as glucose, it is 
chemically distinct. The substitution of a hemiketal group for the hemiacetal group of glucose 
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results in a markedly different fate. The absorption of fructose in the intestines is regulated by 
GLUT5 while glucose uptake is through GLUT4 [226]. Once fructose is absorbed, it is 
delivered to the liver through the portal vein [227]. In the liver, fructose is largely transported 
via GLUT2 and rapidly phosphorylated by fructokinase to form fructose-1-phosphate (F1P). 
Unlike phosphofructokinase, fructokinase activity is not suppressed by ATP [228]. 
Consequently this reaction might be less responsive to cellular energy states, leading to poorer 
regulation of fructolysis [229]. F1P is then metabolised to glyceraldehyde and 
dihydroxyacetone phosphate (DHAP) by aldolase B. Both products can be converted to 
glyceraldehyde-3-phosphate (GA3P). The carbons in GA3P can proceed further down the 
glycolytic pathway into acetyl-CoA, which is either oxidized in the TCA cycle or committed 
towards fatty acid synthesize. The glyceraldehyde can also contribute to lipid synthesize by 
forming glycerol-3-phosphate (G3P) [229]. Hence, the carbons of fructose are fated to end up 
in triglyceride within the hepatocytes.  
Unlike fructose-6-phosphate in glucose metabolism, fructose-1-phosphate can bypass a 
critical regulatory step in glycolysis, generating fructose-1, 6-bisphosphate via the action of 
the energy-sensitive enzyme phosphofructokinase. As a result, fructose is converted into lipid 
unconstrainedly from the cellular control [218, 225]. In addition, Lanaspa and his colleagues 
have demonstrated that mice with fructokinase-deficiency are protected from the adverse 
effects of excessive glucose consumption. It is believed that the polyol pathway in the liver 
converts the excess glucose by aldose reductase (AR) into fructose, which is stored as lipid, 
but only in the presence of fructokinase (Figure 1.7)[215]. As high consumption of fructose 
could cause excess lipid accumulation in the liver, it is hence considered as a “fat sugar”. 
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Figure 1.7 Carbohydrate metabolism. 
Glucose and fructose are dietary sugars. Glucose is most metabolized by glycolysis and can 
be inhibited by ATP or citrate as a feedback response. In the liver, fructose is metabolized to 
glyceraldehyde-3-phosphate (GA3P) or glycerol-3-phosphate (G3P) to form fatty acids or 
triglyceride. It is a biosynthetic pathway that is not regulated by the ATP- or citrate-feedback 
mechanisms. Glucose can also be converted into fructose by the polyol pathway. AR, aldose 
reductases; G-1-P, glucose-1-phophate; G-6-P, glucose-6-phosphate; F-6-P, fructose-6-
phosphate; F-1,6-P, fructose-1,6-bisphosphate; F-1-P, fructose-1-phosphate; DHAP, 
dihydroxyacetone phosphate; FA, fatty acids; TG, triglyceride (Modified from Lyssiotis, C. 
A., et al., Nature, 2013) 
 
1.10 Aims of the thesis and summary of outcomes 
Although enormous progress has been made in our understanding of the role of dietary 
fructose in lipid metabolism and insulin resistance, the mechanisms involved are not 
completely clear. Based on the published literature and preliminary data, the overall aim of 
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this project is to understand the role of lipid accumulation and ER stress on the development 
of insulin resistance in response to different levels of nutrition.  
The experimental models chosen for this research were the high fructose, or high fat fed, mice, 
which show hepatic lipid accumulation and insulin resistance. High fructose fed mice 
exhibited activated UPR while high fat fed mice did not present any ER stress during the 
feeding periods (<8 wk). These models allow the investigation of the effects of lipid- or ER 
stress-reducing strategies on insulin sensitivity. The method chosen to reduce lipid content 
was the oral intake of fenofibrate, to induce PPARα activation. The method chosen to reduce 
ER stress was the i.p. injection of the chemical chaperone, TUDCA to ameliorate ER stress.  
The first aim, discussed in Chapter Chapter 3, was to investigate the role of lipid 
accumulation and ER stress on the initial insulin resistance when the whole body remained 
glucose tolerant. The second aim, discussed in Chapter Chapter 4, was to confirm whether the 
negative effects of ER stress-induced JNK activation on insulin sensitivity remained as a 
predominant trigger when insulin resistance became more developed over time in response to 
over-nutrition consumption. Chapter Chapter 5 discussed the relationships between 
lipogenesis and ER stress in vitro. Chapter Chapter 6 presented the results of the high fat 
model study. However, these data were not completed to understand the different mechanisms 
by which high fructose contributes to insulin resistance.  
Dietary effects on whole-body metabolism are considered to play one of the central roles in 
the pathogenesis of metabolic syndromes. The outcome of this project will provide the 
principle of concept to target lipogenesis and ER-stress, to screen new drugs for the treatment 
of insulin resistance and the metabolic syndrome. This project will also establish a new 
platform for the discovery of new drugs for the treatment of type 2 diabetes. The significance 
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of these studies not only lies in bridging gaps in the current literature, but also in providing 
the basis for drug design and discovery towards preventing and treating type 2 diabetes. 
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2.1 Studies in animals 
All experimental procedures were approved by the Animal Ethics Committees of the RMIT 
University in accord with to the Australia National Health and Medical Research Council 
guidelines. 
Male C57BL/6J mice, obtained from the Animal Resources Center (Perth, Australia), were 
communally housed at 22±1o C on a 12 hours light/dark cycle in the Research Animal 
Facility at RMIT University. All animals were given free access to food (standard pellet diet) 
and water ad libitum. In different studies, animals were fed with either high fat or high 
fructose diets which will be described later. Bodyweight and food intake were measured daily.  
After the acclimatization for approximately 1-2 weeks, the mice were fed either chow (CH), 
high fructose (HFru) or high fat (HFat) diets. Chow-fed mice, with normal insulin sensitivity, 
were maintained in the chow diet during the study period, with free access to food and water.  
The insulin resistance/ER stress/DNL models consist of mice fed either HFru or HFat for the 
relative period. The details will be described in following chapters. Both HFru and HFat diet 
were prepared weekly from the ingredients presented in Table 3 and kept in the fridge until 
use. The composition of the chow diet as percentage of total calories was 23% protein, 71% 
carbohydrate, and 6% fat. The composition of the HFru diet as percentage of total calories 
was 21% protein, 70% carbohydrate, and 9% fat. The composition of the HFat (60%) diet as 
percentage of total calories was 20% protein, 23% carbohydrate, and 60% fat. These diets 
were with the equal quantities of fiber, vitamins, and minerals to the standard diet [193]. 
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Table 3 Composition of the diets. 
  Component g/kg Component g/kg 
Digestible energy 
kcal/kg 
HFru 
diet 
Casein 169.0 Methionine 1.7 
3.569 
Fructose 295.8 Gelatine 12.7 
Cornstarch 295.8 Choline Bitartate 3.9 
Mineral Mix 44.8 Safflower Oil 5.2 
Trace Minerals(ICN) 12.5 Lard 32.0 
BRAN 33.8 AIN Vitamins 8.5 
HFat diet 
(60%) 
Casein 255.6 Methionine 2.6 
5.397 
Sucrose 85.6 Gelatine 19.2 
Cornstarch 170.0 Choline Bitartate 4.5 
Mineral Mix 44.7 Safflower Oil 47.8 
Trace Minerals(ICN) 12.8 Lard 293.4 
BRAN 51.1 AIN Vitamins 12.8 
Chow 
diet 
 
The standard chow diet (CH; Meat Free Rat and Mouse 
Diet) was purchased from Specialty Feeds, Western 
Australia. 
3.34 
 
2.1.1 Determination of whole-body energy expenditure and fat oxidation 
The oxygen consumption rate (VO2) and carbon dioxide production rate was assessed using 
comprehensive laboratory animal measurement system (CLAMS, Columbus Instruments, 
USA). Mice were weighed and placed in the metabolic chamber at 5 pm. After overnight 
acclimation, VO2 and CO2 production were measured in individual mice at 18 min intervals 
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over a period of 24 hours period at a constant environmental temperature (22 oC). Respiratory 
exchange rate (RER) was calculated from VO2 and CO2 production and the values are in 
reverse proportion to whole-body fat oxidation.  
 
2.1.2 Glucose tolerant test (GTT) 
Glucose tolerant test (GTT) is a standard procedure to assess how quickly exogenous glucose 
can be cleared from blood. Glucose intolerance is an indication of impaired glucose 
homeostasis such as insulin resistance and diabetes. 
Mice were fasted for 4 hours with free water supply before experiment. After basal blood 
glucose level was measured, glucose (3 g/kg bodyweight) dissolved in saline was injected 
intraperitoneally. Mice were then put back into the cages. Blood glucose level was measured 
at 15, 30, 60, 90 minutes and blood samples were collected at each time point. The 
incremental area under curve (iAUC) was calculated to assess the glucose tolerance.  
 
2.1.3 Plasma measurements and assays 
Blood samples were collected by reopening the tail wound using a heparin capillary tube 
(Hirschmann Laboratory, Germany) to prevent clotting and haemolysis. Blood glucose level 
was measured using a glucometer (AccuCheck Proforma Nano; Roche, Victoria, Australia). 
Plasma samples were derived from supernatant of the blood samples after centrifuging at 
13000 rpm for 2 min. 5 μl of plasma sample was added into 96 well plates with a 
Peridochrom Triglyceride GPO-PAP kit (Roche Diagnostics, Australia). Plasma insulin level 
was determined using a commercial insulin radioimmunoassay kit (Merck Millipore, #SRI-
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13K). This method is based on a double antibody technique, using 125I-labelled insulin and 
specific mouse insulin antiserum.  
 
2.1.4 Tissue assay methods 
2.1.4.1 Tissue fractionation 
Approximate 70 mg of fresh liver tissue was homogenized in 350 μl of HES 
(HEPES/EDTA/sucrose) buffer [230]. Then samples were centrifuged at 25,000 g for 10 min 
at 4 oC. The supernatant plasma was collected into new tubes for analysis. The pellet was 
suspended with 100 μl of HES buffer and centrifuged under the same condition as before and 
the supernatant was discarded. The pellet which was the nucleus was resuspended with 100 μl 
of HES buffer and then homogenized with a 25-G7/8 needle. 
100 mg of fresh tissue was homogenized in 1 ml of homogenization buffer A. 400 μl of 3% 
sucrose was layered on top of the homogenate and samples were centrifuged at 100,000 g for 
1 h at 4 oC. The lipid layers were removed with a 23-G1 needle and the plasma was removed.  
The pellet was resuspended in 700 μl Buffer A for DAG analysis or 700 μl Buffer B and other 
reagents for protein analysis.  The samples were then homogenized with a 25-G7/8 needle, 
and centrifuged at 20,800 g for 15 min at 4 oC. The remaining floating lipid was removed with 
a 23-G1 needle and Triton-X was added (2%) to the supernatant of the samples for protein 
analysis, or the supernatant was completely removed and the pellet was suspended in 700 μl 
Buffer A for DAG analysis. Membrane samples were then passed through a 28-G1/2 needle 
and stored at -20 oC for DAG analysis. The supernatant membrane fraction was removed and 
saved. Proteins in the lipid fraction were precipitated in acetone at -20 oC overnight, and then 
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centrifuged at 20,800 g for 30 min at 4 oC. The protein pellet was then dried under N2 and 
resuspended in Buffer B with 2% Triton-X [231].  
Table 4 Composition of the buffers for tissue fractionation. 
HES buffer 
20 mM Hepes, pH 7.4, 1 mM EDTA, 250 mM sucrose and protease and 
phosphatase inhibitors 
Buffer A 
20 mM Tris- HCl (pH 7.4), 1 mM EDTA, 0.25 mM EGTA, 250 mM 
sucrose, protease and phosphatase inhibitors 
Buffer B 
20 mM Tris- HCl (pH 7.5 at 4 oC) 
Reagents with 
Buffer B 
150 mM NaCl, 50 mM NaF, 5 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1 
mM PMSF, protease and phosphatase inhibitors 
 
2.1.4.2 Tissue triglyceride content 
Frozen tissue samples were homogenized in CHCl3 : MeOH (2:1) using a hand-held glass 
homogenizer to extract triglycerides. The homogenate was then transferred to a clean tube. 
The homogenizer was rinsed with a further CHCl3 : MeOH, which was added to the 
homogenate. The tube were tightly capped and rotated at room temperature overnight to 
ensure the solubilisation of the triglyceride. 1 mM of NaCl was added afterwards, thoroughly 
mixed and the tubes were centrifuged at 450 g for 15 min to separate the aqueous from 
organic phases. The lower organic layer, containing the triglyceride, was carefully transferred 
to a glass vial and dried completely under air at 45 oC. The pellet was redissolved in an 
appropriate amount of ethanol depending of the tissue. The tissue triglyceride level was 
determined using a commercial kit (Peridochrom Triglyceride GPO-PAP kit, Roche 
Diagnostics, Australia), against a standard curve [193].  
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2.1.4.3 Determination of tissue diacylglycerol and ceramide  
Lipids were extracted from liver homogenates that were mentioned in 0 using CHCl3: MeOH : 
PBS+0.2% SDS (1:2:0.8). Diacylglycerol kinase and 32P-labelled ATP (0.55 GBq/mmol cold 
ATP) were added to the lysates pre-incubated with cardiolipin/octylglucoside. During the 
reaction, DAG and ceramide were converted in to 32P-phophatidic acid and 32P-ceramide-1-
phosphate respectively. The reaction was stopped after 2.5 hours by the addition of CHCl3: 
MeOH (2:1) and 1% perchloric acid. To separate the radioactive products, the tubes were 
centrifuged at 2000g for 2 min. The upper aqueous layer containing unreacted 32P-ATP was 
discarded and the organic payer was washed twice with CHCl3, centrifuged and upper phase 
discarded. The organic layer was dried under N2 and stored at -20 
oC overnight.  
To separate and quantify of 32P-phosphatidic acid and 32P-ceramide-1-phosphate, the samples 
were spotted onto thin-layer chromatography (TLC) plates. For the accurate comparison 
between plates, each plate contained one blank, one DAG and one ceramide standards. The 
plates were placed in the pre-saturated TLC tanks containing CHCl3: MeOH: ammonium 
hydroxide (65:35:7.5 v/v/v), until the solvent reached the top of the plate. Following 
approximately 30 min drying period, the plates were place in the pre-saturated TLC tank 
containing CHCl3: MeOH : acetic acid : acetone : water (10:2:3:4:1 v/v/v/v/v) until the 
solvent reached the top of the plate. This procedure optimized the separation of 32P-
phosphatidic acid and 32P-ceramide-1-phophate. The plates were dried for 30 min and placed 
in black phosphorimager cassettes overnight. The plates were then developed. 32P-labelled 
phosphatidic acid and ceramide-1-phosphate were identified by autoradiography, dried, 
scraped from the TLC plates and counted in a liquid scintillation analyser (LS6500, Beckman 
Counter Inc, USA) [232]. 
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2.1.4.4 Measurement of hepatic fatty acid oxidation 
Fatty acid oxidation was measured in liver homogenates. Liver samples were homogenized in 
ice-cold 250 mmol/l sucrose, 10 mmol/l Tris-HCl, and 1 mmol/l EDTA, pH 7.4. For 
assessment of substrate oxidation, 50 μl of liver homogenate was incubated with 450μl 
reaction mixtures (pH 7.4). Final concentration of the reaction mixture were: 100 mmol/l 
sucrose, 80 mmol/l KCl, 10 mmol/l Tris-HCl, 5 mmol/l KH2PO4, 1 mmol/l MgCl2, 2 mmol/l 
malate, 2 mmol/l ATP, 1 mmol/l dithiothreoitol, 0.2 mmol/l EDTA and 0.3% fatty acid free 
BSA. The homogenate was incubated at 30 °C for 90 min in the reaction mixture containing 
0.2 mM [178]-palmitate (0.5 μCi), 2 mM  L-carnitine and 0.05 mM Coenzyme A. The 
reaction was stopped by the addition of 100 μl of ice-cold 1 M perchloric acid. CO2 produced 
from the reaction was captured in 1 M NaOH. 14C counts in the acid-soluble fraction were 
combined with the CO2 values to give the total palmitate oxidation rate [232].  
 
2.1.4.5 Measurement of hepatic de novo lipogenesis  
Hepatic de novo lipogenesis was assessed by measuring the incorporation of [44, 45, 178]-
H2O into triglyceride in the liver. Mice were injected with [44, 45, 178]-H2O (20 μCi/g BW, 
ip) before tissue collection.  Liver samples were collected at 90 minutes for the measurement 
of radioactivity in liver triglyceride against the count in plasma using a β-scintillation counter 
(Tricarb, Bio-Rad, USA).  
 
2.1.4.6 Citrate synthase assay 
Citrate synthase is a critical enzyme in the Krebs cycle. It is localized in the mitochondrial 
matrix and commonly used as a quantitative marker enzyme for the capacity of intact 
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mitochondria [233]. Mitochondria proliferation is normally associated with an increase of 
citrate synthase activity. Citrate synthase catalyzes the reaction of 2 carbon acetyl CoA to 
form 6 carbon citrate and hence to regenerat coenzyme A [234]. The citrate synthase assay is 
a spectrophotometric enzyme assay. The optical density of the liquid sample is related to the 
absorbance. The rate of increase of the absorbance appears to be the slope which is 
proportional to enzyme activity. In the spectrophotometer, the reaction catalyzed by citrate 
synthase is coupled to the irreversible chemical reaction. The product of the reaction 
(thionitrobenzoic acid) is an absorbing substance with intense absorption at 412nm. The 
absorbance increases linearly with time.  
Frozen samples were homogenized in 165 mmol/l KCL and 1.98 mmol/l EDTA-containing 
buffer (pH 7.4) with a glass homogenizer before being subjected to three freeze-thaw cycles. 
Samples were added to 96 well plates with working solution that shown in Table 5 for blank 
reaction which was red at 412 nm over 2 min at room temperature. Then oxaloacetic acid was 
added to each well to initiate the main reaction and the change of the absorbance was 
recorded [235]. 
Table 5 Working solution of citrate synthase assay. 
Reagent (10 ml) 
100 mM Tris buffer 7 ml 
1 mM DTNB 1 ml 
3 mM acetyl CoA 1.5 ml 
10% Triton X-100 250 μl 
dH2O   250 μl 
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Equation for calculation:  
Acitivity =
Change in absorbance per minute × Volumetotal × dilution factor 
Extinction coefficient × Volumesample  × Optic path − length
 
Where: 
Change in absorbance per min = ∆ Abs./min 
Volume Total = 0.5 ml for cuvette, 0.2 ml for microplate 
Dilution factor = 40 for 1:50 dilution or 100 for 1:100 dilution 
Extinction Coefficient = 6.22 μmol/cm2 
Optical path-length= 1 cm for cuvette, to be determined for microplate 
Volume Sample = 0.02 ml for microplate 
 
 
  
2.1.4.7 β3-hydroxyacyl-CoA dehydrogenase activity assay 
β3-hydroxyacyl-CoA dehydrogenase (β-HAD) is an oxidoreductase which catalyzes the third 
step of β-oxidation, converting the hydroxyl group to a keto group and forming the end 
product 3-ketoacyl CoA [236]. The β-HADIRE1 assay is based on the reverse reaction. 
Enzyme activity is calculated according to the disappearing rate of NADH over time.  
The sample preparation was the same as mentioned in 2.1.4.6. The supernatents were then 
added into 96 well plates with the assay solution. The plate was then incubated in the 
spectrophotometer for 5 minutes at room temperature and red the blank reaction at 340 nm. 
Additional 4 μl acetoacetyl-CoA was added to each well. The decrease in absorbance was 
recorded in spectrophotometer for at least 3 minutes. 
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Table 6 Assay solution of β-HAD assay. 
  Reagent volume (ml) 
 
[63] Tris-HCl  1.25 
 
[200 mM] EDTA 0.25 
 
[5 mM] NADH 1.25 
  H2O 22.25 
For 96 well plate method, 10% Triton X need to be added to the assay solution. 
Equation for calculation:  
β − HADactivity (μmol g min⁄⁄ )
=
(Rate of disappearance of NADH × Volumetotal) × dilution fator
Extinction coefficient × Optical path − length × VolumeSample
  
Where: 
Rate of disappearance of NADH = ∆ Abs./min 
Volume Total = 0.5 ml for cuvette, 0.2 ml for microplate 
Dilution factor = 40 for 1:50 dilution or 100 for 1:100 dilution 
Extinction Coefficient = 6.22 μmol/cm2 
Optical path-length= 1 cm for cuvette, to be determined for microplate 
Volume Sample = 0.01 ml for microplate 
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2.2 Cell culture procedures 
2.2.1 General procedures 
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin-streptomycin-glutamine (PSG) or 
1% (v/v) penicillin-streptomycin (PS) at 37 °C in 5% CO2. All above culture reagents were 
obtained from Invitrogen (Melbourne, Australia). The cell culture medium was changed every 
two or three days. Cell passages of 5 to 20 were used for all experiments. Briefly, cells were 
sub-cultured at 1 in 5 dilutions when cells reached 70-80% of confluence. Subculture was 
made by rinsing the cells first with 1x phosphate buffered saline (PBS) buffer (0.2 M NaCl, 
10 mM Na2HPO4, 3 mM KCl, 2 mM KH2PO4, pH 7.4), then adding 1~2 ml of 1x trypsin-
EDTA solution (Sigma-Aldrich, Melbourne, Australia) to detach the cells from the T75 flask 
(usually within 1 min). Cells were then centrifuged at 100 g for 5 mins and re-suspended in 
~5 ml of fresh culture medium and were transferred with desired amount into a new T75 flask 
containing fresh growth medium. 
 
2.2.2 Storages of cells 
Cells were washed with 1x PBS, trypsinized with 1x trypsin-EDTA solution and incubated at 
37 °C for 1~2 mins. Cells were then rinsing with 5 ml normal culture media per T75 flask and 
centrifuged at 100 g for 5 mins. Supernatant was aspirated. The remaining cell pellet was re-
suspended in 0.5 ml of DMEM / 20% FBS / 15% DMSO / 1% PS or PSG to re-suspend cells, 
mixed. Then 1 ml aliquots were prepared in each cryovial. Cryovials were then wrapped in a 
clean paper towel and transferred to a Nalgene® cryo 1°C freezing container (Thermo Fisher 
Scientific, Australia) filled with 100% isopropanol (Sigma-Aldrich, #I9516), and stored 
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overnight at -80 °C. The next day, one of the frozen vials was defrosted to test cell viability 
while the rest of vials were placed in liquid nitrogen for long-term storage. 
 
2.2.3 Counting of cells number 
Cell numbers were counted using haemocytometer (Grace Davison Discovery Sciences, 
Australia). In general, 100 µl of well-mixed cells suspension was placed into the counting 
area of a clean haemocytometer and counted under a microscope (10x or 20x objectives) and 
counted (4 x 16 corner squares). Cell concentration were calculated by dividing the total 
number of counted cells by 4 and multiplying by 2, from all 4 corners of  the haemocytometer 
(Figure 2.1) 
 
Figure 2.1 Hemocytometer. 
The calculation formula of counting cells using hemocytometer is: 
𝐶𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑚𝑙⁄ =  𝐶𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑛𝑢𝑚𝑏𝑒𝑟 4 × 104⁄  
Where: 
Counted cells number = Cells number of Sum ( Area1 + Area2 + Area3 + Area4) 
After cells number reached a desired confluence, the cells were seeded into suitable plate for 
further experiments. 
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2.3 Western Blotting 
2.3.1 Protein extraction 
Frozen tissues were kept on ice and homogenised with ice-cold RIPA buffer (pH 7.4, Table 7) 
with a pestle mixer. After incubating with lysis buffer for 2 hours at 4 oC, the samples were 
centrifuged at 13,000 rpm for 10 min at 4 oC. The supernatant was collected for further 
experiments or stored at -80 oC. 
Table 7 RIPA buffer. 
Stock Fresh 
Tris   65 mM NaF 10 mM 
NaCl 
 
150 mM NA3VO4 1 mM 
EDTA 
 
5 mM PMSF 1 mM 
NP-40 
 
1% 
protease/phosphatase 
inhibitors 
10 ul/ml 
Na-deoxycholate 0.50% 
SDS 
 
0.10% 
glycerol   10% 
 
2.3.2 Protein assay 
The protein concentration of homogenate was determined by the BCA protein assay using a 
commercial kit (Sigma-Aldrich, #B9643). Samples were diluted from 1:5 to 1:50, depending 
on the specific tissues being assayed, with lysis buffer and added into 96-well plate with 
duplications.  The standard was the bovine serum albumin (BSA) which was diluted to 
different concentration. Working reagent was made following the manufacturer’s instructions 
and pipetted to the plate to start the reaction. The plate was incubated at 37 oC for 30 minutes 
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and read in the spectrophotometer. Protein concentration of the samples was calculated from 
the standard curve. An aliquot of the samples was dissolved in the Laemmli buffer to obtain 
equal amounts of protein in all samples. The samples were heated at 37 oC for 30 minutes or 
90 oC for 10 minutes to denature, depending on the specific protein being assayed. 
 
2.3.3 SDS-PAGE and immunodetection of protein 
Plates were assembled following the manufacturers’ instruction (Biorad, Sydney, NSW, 
Australia). The 8%, 10% or 12% Tris-glycine based gels (1.5 M Tris, pH 8.8, 30% acrylamide, 
10% SDS, distilled water, 10% ammonium persulfate and TEMED) were prepared and 
transferred to the glass plates as running gels. The EtOH was added on the top of the gels to 
remove bubbles. The solution in the plate was left to set at room temperature. Once the 
running gel had set, the EtOH was removed and a 4% stacking solution (0.5 M Tris, pH 6.8, 
30% acrylamide, 10% SDS, distilled water, 10% ammonium persulfate and TEMED) was 
layered on top of the running gel. The comb was inserted the solution was left to polymerize 
at room temperature. Gels were stored in running buffer at 4 oC until use.  
Equal amounts of protein samples were loaded into wells on the gels and run with the protein 
ladder (Biorad, Sydney, NSW, Australia) in a tank filled with running buffer (25mM Tris, 192 
mM glycine, 0.1% SDS, pH 8.9). Electrophoresis was performed at 130 V until the separation 
was completed.  
The gels were then carefully removed from the plates and stored in ice-cold transfer buffer 
(25 mM Tris, 192 mM glycine, 20% MeOH) temporarily. When the preparation of sponges 
and blotting papers was ready, the gel and membrane were sandwiched between sponge and 
paper and were clamped tightly together after checking air bubbles between the gel and 
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membrane. The whole set was then placed in a tank filled with transfer buffer and protein was 
transferred from gels to activated PVDF membranes (Biorad, Sydney, NSW, Australia) at 90 
V for 2 hours. Ponceau red staining was used to confirm the transfer of protein.  
Non-specific binding was blocked with 3% bovine serum albumin in Tris Buffered Saline 
plus 0.1% Tween-20 (TBST) for 1 hour at room temperature or overnight at 4oC. The 
membranes were washed with TBST and incubated with the primary antibody (Table 8) for 2 
hours at room temperature or overnight at 4oC. The membranes were then washed with TBST 
several times to remove the unbound antibody. The wash was followed by the incubation with 
a respective secondary antibody for at least 2 hours at room temperature. After washing with 
TBST for 6 times, chemiluminescence reagent was used to detect the bound antibody to 
visualise the protein bands. The protein bands of interest were quantified using commercial 
software (Image Lab v4.1, Biorad Laboratories, 2012).  
After the development of specific proteins, membranes were stripped with a stripping buffer 
(1 M Tris-HCl, pH 6.7, 20% SDS) at 60oC for 30 minutes. To confirm whether the membrane 
was stripped completely or not, the membrane was blocked with 3% BSA in TBST solution 
and incubated with secondary antibody for 1 hour at room temperature. The membrane then 
was developed with chemiluminescence solution and the loss of protein bands indicated that 
stripping was successful. The stripped membrane can be used to probe for other proteins.  
Table 8 List of antibodies. 
Name Company Name Company 
p-Akt (Ser 473) Cell Signaling  p-IRS1(Ser307) Cell Signaling  
t-Akt Cell Signaling  CHOP Santa Cruz 
p-GSK3β Cell Signaling  p-IRE1 Abcam 
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Name Company Name Company 
t-GSK3β Cell Signaling  XBP1 Santa Cruz 
SREBP1c Santa Cruz ATF6 Santa Cruz 
FAS Cell Signaling  p-IKKα/IKKβ Cell Signaling  
ACC Cell Signaling  IκBα Cell Signaling  
SCD1 Cell Signaling  p-JNK Cell Signaling  
ACOX1 Santa Cruz t-JNK Cell Signaling  
p-PERK Cell Signaling  p-cJun Cell Signaling  
p-eIF2α Cell Signaling  t-cJun Cell Signaling  
GADD34 Cell Signaling  PKCε Cell signaling  
 
2.4 Statistical analysis 
Results were expressed as mean ±SE throughout the thesis. For the comparison of more than 
two groups, one-way analysis of variance (ANOVA), followed by Tukey-Kramer multiple 
comparisons test, were performed to assess statistical significance between groups. A 
Student’s t test was used where only two groups were compared. The analysis was performed 
using a commercial software package (GraphPad Prism, 5.01, GraphPad Software Inc. USA). 
P<0.05 was considered statistically significant. 
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3.1 Introduction 
For the past three decades, the consumption of fructose has increased in parallel with the 
increasing prevalence of obesity [237]. Experimental evidence has demonstrated that 
consumption of diets high in fructose (HFru) results in increased de novo lipogenesis (DNL), 
ectopic lipid accumulation, insulin resistance, and obesity in animals [160, 232, 238, 239], as 
well as in humans [224, 225, 240, 241]. In line with this, we [193] and others [161] have 
detected increased DNL, and ectopic lipid accumulation along with activated UPR signaling 
and impaired insulin sensitivity in the liver of mice after feeding for one week on a HFru diet. 
This supports the role of the liver being the unique organ that is capable of metabolising 
fructose as an energy source [242], and such metabolism can rapidly lead to the development 
of insulin resistance with the liver being the first tissue to be affected.  
Under the state of insulin resistance, the liver becomes less responsive to the regulatory 
effects of insulin on glucose production and glycogen synthesize leading to the subsequent 
manifestation of fasting hyperglycemia [243]. Although the cause of hepatic insulin resistance 
can be multifactorial [244], excessive lipid accumulation from DNL and prolonged UPR 
signaling appears to be the key mechanism during HFru feeding [160, 232] as reviewed in 
detail in 1.5.1. However, mice harbouring overexpression of diacylglycerol acyltransferase 2 
(DGAT2) in the liver, which catalyzes the esterification of DAGs to triglyceride, did not 
manifest with insulin resistance, despite marked hepatic steatosis associated with increased 
DAG content [245]. This suggests additional factors other than lipid accumulation per se 
might be crucial for the development of insulin resistance in the liver.  
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The unfolded protein response (UPR) is increasingly recognized to be a major theme 
implicated in the pathogenesis of hepatic insulin resistance [244]. This has been reviewed in 
1.5.2.  
Alhough β cell failure-induced imapired insulin secretion and insulin resistance are both 
characteristics of type 2 diabetes, insulin resistance is the earliest detectable defect in pre-
diabetic individuals under most situations [246]. Elevated blood glucose concentration can be 
overcome by increasing insulin secretion. However, persistent elevated glucose levels above 
the physiological range leads to β cell failure and hyperglycemia. The subsequent impaired 
glucose tolerance can be diagnosed and is a precursor of type 2 diabetes. To our best 
knowledge, most current in vivo models achieved the phase of glucose intolerance in insulin 
resistance. It still remains unclear the respective implication of these cellular events in the 
onset of the process to develop hepatic insulin resistance by HFru feeding. 
The present study sought to investigate the changes in DNL and UPR signaling, and to 
identify the initiating mechanism for hepatic insulin resistance, in response to acute HFru 
feeding. Our findings demonstrated that enhanced hepatic DNL and UPR signaling are 
detectable as early as 3 days, which were maintained throughout the course of HFru-feeding 
with no signs of critical protein deterioration of either DNL or UPR in the liver. Acute HFru 
feeding was able to impair hepatic insulin signaling along with promoting DNL and the 
activation of only the IRE1 branch of UPR signaling pathway. Inhibition of IRE1 was 
accompanied by attenuation of JNK-mediated serine phosphorylation of IRS and preservation 
of hepatic insulin signaling, despite increased hepatic DNL and marked steatosis. These 
findings suggest the activation of IRE1/JNK is a predominant trigger at the onset of hepatic 
insulin resistance induced by HFru feeding. 
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3.2 Methods 
3.2.1 Animal Studies 
Male C57BL/6J mice (12 weeks old) from the Animal Resources Centre (Perth, Australia) 
were kept at 22±1°C on a 12h light/dark cycle. After 2 weeks of acclimatization, mice were 
fed for either 1 day, 3 days, 1 week or 8 weeks with either normal chow diet (70% calories 
from starch, ~10% calories from fat, and ~20% calories from protein; Gordon's Specialty 
Stock Feeds, Yanderra, Australia) or high fructose (HFru; containing 35% fructose, 35% 
starch, ~10% fat and ~17% protein) as described in our previous studies [193]. HFru diet was 
provided to the mice from 6pm to 2pm (20 hrs) on the following day when they were 
sacrificed. The chemical chaperone TUDCA (Sigma Aldrich Pty Ltd, Australia) was applied 
by i.p. injection (300 mg kg-1 body weight) 4 hours prior to HFru feeding [193, 232, 247]. The 
betulin-treated animals were first fed with chow mixed with betulin (30 mg kg-1 body weight) 
for 1 week and fed with HFru diet mixed with betulin (30mg kg-1 body weight) for overnight 
as HFru diet. All experiments were approved by the Animal Ethics Committee of RMIT 
University.  
Body weight and food intake were measured before and after experiments. After one day of 
feeding, the mice were fasted for four hours before the collection of plasma samples for the 
measurement of insulin levels by radioimmunoassay (Linco/Milipore, Billerica, MA) [232, 
238, 248] and glucose levels using a glucometer (AccuCheck II; Roche, Australia). Tissues of 
interest were collected and freeze-clamp immediately for subsequent analyses. Glucose 
tolerance test (GTT; 2g kg-1 BW, i.p.) was conducted in a separate group of mice following a 
four hours fasting and blood glucose levels were measured at 0, 15, 30, 60 and 90 minutes 
using a glucometer (AccuCheck II; Roche, Australia). The area under curve (AUC) was 
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calculated to estimate glucose intolerance. For the assessment of insulin signaling in the liver, 
5-7 hour-fasted mice were injected with insulin (2U kg-1 BW, i.p.) 20 min prior to tissue 
collection [193, 232]. Insulin tolerance test (ITT; 0.75U kg-1 BW, i.p.) was performed in a 
separate group of mice and blood glucose levels were measured at 0, 15, 30, 60 and 90 
minutes using a glucometer (AccuCheck II; Roche, Australia). The area under curve (AUC) 
was calculated to estimate glucose intolerance. Mice fed with HFru diet for 3 days, 1 week 
and 8 weeks were performed tissue collection following 4 hours fasting.  
3.2.2 Measurement of triglyceride levels  
The details were described in 2.1.4.2. 
3.2.3 Western blotting  
The details were described in 2.3. 
3.2.4 Statistical Analyses 
Data are presented as means ± SE. One-way analysis of variance was used for comparison of 
relevant groups. When significant variations were found, the Tukey-Kramer multiple 
comparisons test was applied. Differences at p<0.05 were considered to be statistically 
significant.  
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3.3 Results 
3.3.1 Time course of hepatic DNL and UPR signaling induced by HFru feeding 
We first examined the expression of key regulating proteins of UPR and DNL signaling in the 
liver in relation to changes in glucose tolerance over a range of different feeding periods. 
Mice fed an HFru diet displayed greater caloric intake starting at day 3 (p<0.05 vs. CH) and 
manifested with glucose intolerance from day 7 as evidenced by the greater area under curve 
(AUC, p<0.05 vs. CH, Table 9). As shown in Figure 3.2Figure 3.2 Time course of hepatic 
UPR and DNL induced by HFru feeding., HFru feeding also resulted in the activation of two 
UPR signaling pathways as indicated by significant increases in phosphorylated-IRE1 (p-
IRE1) and -eIF2α (p-eIF2α, ~2-fold, both p<0.05). Concomitant to the induction of UPR, the 
expression of ACC and FAS, which catalyze the formation of malonyl-CoA and long chain 
fatty acids, respectively, were markedly elevated 3 days after the commencement of HFru 
feeding (5-folds, both p<0.01). These data indicate that both activations of UPR signaling and 
the elevated DNL have reached their maximal levels within 3 days and these changes are 
maintained to week 8. 
 
Table 9. Changes in metabolic parameters of HFru-fed mice over time 
 CH HFru 
Body mass(g)   
Day 0 26.5 ± 0.5 26.9 ± 0.4 
Day 1 27.1 ± 0.4 27.4 ± 0.4 
Day 3 26.5 ± 0.6 27.0 ± 0.3 
Week 1 26.6 ± 0.4 26.9 ± 0.4 
Week 8 27.1 ± 0.6 27.2 ± 0.5 
Caloric intake (kcal/g/day) 
Day 1 
12.6 ± 1.9 14.0 ± 1.3 
Day 3 10.1 ± 0.5 15.6 ± 0.6 * 
Week 1 11.8 ± 0.3 18.4 ± 0.9 ** 
Week 8 14.8 ± 0.4 18.4 ± 0.8 * 
Chapter 3  
 
65 
 
Male C57BL/6J mice were fed either a CH or HFru diet for a period of up to 8 weeks. The 
calculation of caloric intake was based on food intake. AUC stands for the area under curve 
for glucose tolerance tests. Data are means ± SE of 8-10 mice per group. * p<0.05, ** p<0.01 
vs CH-fed mice. +: The curves of glucose tolerance is presented below. 
 
 
Figure 3.1 The curves of glucose tolerance test.   
Glucose tolerance test (GTT) was performed with an injection of glucose (2.5 g/kg, ip) after 
5-7 hours of fasting in HFru-fed mice for one day (A), 3 days (B), 1 week (C) and 8weeks (D). 
 CH HFru 
Blood glucose (mM)   
Day 1 9.2 ± 0.2 9.2 ± 0.4 
Day 3 9.3 ± 0.9 9.0 ± 0.5 
Week 1 8.4 ± 0.3 9.5 ± 0.2 ** 
Week 8 9.2 ± 0.2 11.7 ± 0.6 * 
Plasma insulin (pg/ml)   
Day 1 1267 ± 131 1841 ± 244 ** 
Day 3 1345 ± 150 1474 ± 146 
Week 1 NA NA 
Week 8 1276 ± 116 1450 ± 174 
AUC for GTT+   
Day 1 1136 ± 62 953 ± 76 
Day 3 1044 ± 48 1098 ± 73 
Week 1 1046 ± 32 1256 ± 986 * 
Week 8 1020 ± 39 1394 ± 70 ** 
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Figure 3.2 Time course of hepatic UPR and DNL induced by HFru feeding. 
Male C57BJ/6J mice (10-12 weeks old) were fed a high fructose (HFru) diet for up to 8 weeks. 
Liver tissues were collected after 3 days, 1 week and 8 weeks and immunoblotted for key 
markers of UPR signaling: phosphorylated-IRE1 and -eIF2α and fatty acid synthesis: ACC 
and FAS. The day 0 refers to the chow-fed mice. The fold changes of proteins are calculated 
against housekeeping proteins (GAPDH). * p<0.05; ** p<0.01 compared with the baseline 
(Day 0). Data are mean ± SE of 6-8 mice per group. 
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3.3.2 One day feeding of HFru diet stimulated DNL and lipid accumulation in the liver 
but not in muscle or adipose tissue 
As both DNL and UPR signaling pathways were induced in parallel by HFru feeding from 3 
days onwards, we next examined the effect of one day feeding of HFru diet in an attempt to 
identify which of these cellular events was triggered earlier. One day feeding of HFru was 
able to increase the expression of key regulators of DNL in the liver, namely ACC (2.3-fold), 
FAS (2.3-fold), mSREBP-1c (1.5-fold) and SCD1 (2.5-fold, all p<0.05 vs. CH, Figure 3.3A). 
Consistent with this, hepatic TG content was also increased by 2.1-fold (p<0.01 vs. CH, 
Figure 3.3A right hand panel). In contrast, no significant differences were detected for any of 
these key regulators for DNL in skeletal muscle (Figure 3.3B) and white adipose tissue 
(Figure 3.3C). Accordingly, the content of TG remained unaltered in skeletal muscle 
following one day feeding of HFru (Figure 3.3B). These results suggest that one day feeding 
of HFru diet is sufficient to trigger DNL and such effect is confined to the liver. 
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Figure 3.3 Hepatic DNL and lipid accumulation induced by one day feeding of HFru diet. 
Mice were exposed for one day feeding of HFru diet. The expression of lipogenic enzyme: 
ACC, FAS, matured SREBP-1c and SCD1 were determined by immunobloting of whole cell 
lysate from liver (A), skeletal muscle (B) and epididymal white adipose tissue (C). 
Representative western blots are shown. Tissue triglyceride (TG) content was determined 
following 4 hours of fasting. Data are mean ± SE of 6-8 mice per group. * p<0.05 compared 
with CH; ** p<0.01 compared with CH. 
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3.3.3 One day feeding of HFru diet activated the IRE1 and XBP1 splicing in the liver 
As the PERK and IRE signaling arms (but not the ATF6 arm) of the UPR pathways were both 
activated after 3 days HFru feeding, we next examined whether both or only one of these two 
arms of UPR may be activated in the liver following one day feeding of HFru diet. As shown 
in Figure 3A, the p-IRE1and the splicing of its downstream effector XBP1 (sXBP1) were 
significantly augmented following one day feeding of HFru diet (2 to 2.5 fold, respectively, 
both p<0.01 vs. CH). However, no significant differences were found in the phosphorylation 
of eIF2α (p-eIF2α) or the expression level of CHOP, a downstream protein of the PERK 
branch [249]. Similarly, the maturation of ATF6 in the liver remained unaffected by one day 
feeding of HFru diet (Figure 3.4A). Consistent with the lack of changes in DNL in skeletal 
muscle and white adipose tissue, no significant differences were found in any of the measured 
UPR protein markers in these tissues (Figure 3.4B, C) compared to CH-fed mice. These data 
indicate that one day feeding of HFru diet is able to trigger the activation of specific UPR 
signaling in the liver involving the IRE1 arm. 
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Figure 3.4 Activation of IRE1/XBP1 branch in the liver by one day feeding of HFru diet. 
Mice were exposed to one day feeding of HFru diet. Protein expression of key UPR signal 
transducers: phosphorylated-IRE1, spliced XBP1, phosphorylated-eIF2α, CHOP and matured 
ATF6 were determined by immunobloting of whole cell lysate from liver (A), skeletal muscle 
(B) and epididymal white adipose tissue (C). Representative western blots are shown. Data 
are mean ± SE of 6-8 mice per group. * p<0.05 compared with CH; ** p<0.01 compared with 
CH. 
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3.3.4 One day feeding of HFru diet impaired hepatic insulin signal transduction  
We next questioned whether insulin signal transduction might be affected by the one day 
feeding of HFru diet. This was associated with an increased activity of JNK, as evidenced by 
the increased phosphorylation of JNK (p-JNK, 1.6-fold, p<0.05 vs CH) and its downstream 
effector c-Jun (p-c-Jun, 1.5-fold, p<0.05 vs. CH). Consistent with enhanced JNK activation 
we also observed a 50% increase in serine phosphorylation of IRS (p-IRS, p<0.05 vs. CH, 
Figure 3.5A) in the liver. As expected, the insulin-stimulated phosphorylation of Akt (p-Akt) 
was markedly reduced by 30% in the liver (p<0.05 vs. CH insulin stimulated) following one 
day feeding of HFru diet. Consistently, HFru-fed mice showed insulin intolerance as indicated 
by decreased reversed-AUC of ITT (Figure 3.9A). In addition, mTOR which can be enhanced 
by either insulin or HFru [250] showed a significant reduction with the presence of insulin in 
HFru-fed mice compared with relative control (Figure 3.9B). No detectable defects in the 
insulin-stimulated phosphorylation of Akt were found in response to one day feeding of HFru 
diet in skeletal muscle and white adipose tissue (Figure 3.5B and C). These results indicate 
that HFru diet is sufficient to impair hepatic insulin sensitivity and this impairment is closely 
correlate with the activation of IRE1 pathway. 
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Figure 3.5 Impaired hepatic insulin signal transduction by one day feeding of HFru diet. 
Mice were fed for HFru diet for one day. Insulin signal transduction was assessed by 
immunoblotting of key proteins: phosphorylated-Akt (serine 473), -JNK (Threonine 183/ 
Tyrosine 185) and -c-Jun (serine 63) and p-IRS1 (serine 307) in whole cell lysate of liver (A), 
skeletal muscle (B) and epididymal white adipose tissue (C). Representative western blots are 
shown. Data are mean ± SE of 6-8 mice per group. * p<0.05 compared with CH; # p<0.05 
compared with CH+ insulin. 
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3.3.5 Inhibition of IRE1 activity attenuated hepatic DNL induced by one day feeding of 
HFru diet. 
To investigate the relationship between the activation of the IRE1 branch upon HFru feeding 
and the concomitant increase in DNL and the impairment of insulin signaling transduction, 
we next examined whether dampening the activation of IRE1 with the chemical chaperone 
TUDCA [214] was able to reverse any of these events in the liver of HFru-fed mice. 
Administration of TUDCA to HFru-fed mice did not affect the levels of blood glucose, food 
intake or body weight, but normalized plasma levels of insulin (Table 10). As shown in Figure 
3.6A, TUDCA administration abolished the increased phosphorylation of IRE1 and splicing 
of XBP1 induced by HFru feeding (p<0.05 vs. HFru). Along with the inhibition of IRE1 upon 
TUDCA treatment, the expressions of mSREBP-1c ACC, FAS, and SCD1 were also reduced 
to levels comparable to the CH-fed mice (Figure 3.6B), indicating that IRE1 activity is a 
major inducer for the enhanced hepatic DNL observed in the one day HFru-fed mice. 
To exclude the possibility of metabolic effect of bile acids in the liver, we next administrated 
another compound, betulin to suppress ER stress. Betulin belongs to different class of 
compounds from TUDCA and it has been reported as a SREBP-1c inhibitor. In the current 
study, betulin showed similar effects on lipogenesis (Figure 3.8A) and ER stress (Figure 3.8B) 
as TUDCA. The suppression of DNL and ER stress abolished the impairment of hepatic 
insulin signaling transduction (Figure 3.8D-F) indicated by the suppression of p-IRS1ser307 and 
restored p-Akt with insulin stimulation. However, betulin failed to reduce the hepatic 
triglyceride in current study (Figure 3.8C).  
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Table 10 Basal metabolic parameters of TUDCA treated mice 
 CH HFru HFru+TUDCA HFru+Betulin 
Body mass (g) 24.4 ± 0.3 25.5 ± 0.8 25.8 ± 0.5 24.3 ± 0.3 
Caloric intake 
(kcal/g/day) 
12.6 ± 1.9 14.0 ± 1.3 14.3 ± 1.2 14.8 ±1.6 
Blood glucose (mM) 9.1 ± 1.0 9.0 ± 0.5 9.1 ± 0.3 9.5 ± 0.4 
Plasma insulin (pg/ml) 1267 ± 131 1841 ± 244* 1134 ± 246 NA 
Male C57BL/6J mice were fed either a chow (CH) or fructose-rich diet (HFru) for 1 day. The 
calculation of caloric intake was based on food intake (3.11 kcal/g for CH diet and 3.569 
kcal/g for HFru diet). The animal was injected with TUDCA or vehicle four hours prior to 
feeding. Data are means ± SE of 5-10 mice per group. * p<0.05 vs CH-fed mice. 
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Figure 3.6 Inhibition of IRE1 activity attenuated hepatic DNL.  
The chemical chaperone TUDCA was administered 4 hours prior to the commencement of 
one day feeding of HFru diet. The activity of IRE1 in the liver was determined by 
immunobloting of phosphorylated-IRE1 and spliced XBP1 in whole cell lysate (A). Hepatic 
DNL was assessed by immunoblotting of: ACC, FAS, matured SREBP-1c and SCD1 (B).  
SREBP-1c, ACC, FAS and SCD1 were determined by immunoblots from liver tissue. 
Representative blots are shown. Data are mean ± SE of 6-8 mice per group. * p<0.05 
compared with CH; # p<0.05 compared with HFru. 
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3.3.6 Inhibition of IRE1 activity protected hepatic insulin signaling transduction by 
diminishing JNK activity. 
Consistent with a reduction of the activity of IRE1, TUDCA administration also completely 
abolished the activation of JNK induced by one day feeding with HFru diet, as evidenced by 
the reduced phosphorylation of JNK and c-Jun (both p<0.05 vs. HFru, Figure 3.7A). This was 
associated with a concomitant reduction of IRS1 serine phosphorylation and restored insulin-
stimulated phosphorylation of Akt in the liver. Intriguingly, the restored hepatic insulin 
signaling upon TUDCA treatment was found to be independent of any changes of TG content 
in the liver (Figure 3.7C). As membrane-associated PKCε has been demonstrated to be a key 
driver of impaired insulin signaling by lipid accumulation [139, 251], we hence measured the 
content of membrane-associated PKCε to further assess the role of lipid accumulation in the 
onset of impaired hepatic insulin signaling transduction induced by fructose. No significant 
differences were found in the membrane-associated PKCε following one day feeding of HFru 
diet compared to CH-fed mice (Figure 3.7D). TUDCA treatment also significantly reduced 
microsomal TG transfer protein (MTTP, Figure 3.7E), a protein required for the hepatic TG 
export. These results support the hypothesis that increased lipid content is unlikely to be a 
major contributing factor to the onset of hepatic insulin resistance induced by fructose. 
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Figure 3.7 Inhibition of IRE1 activity down regulated JNK activity and protected hepatic 
insulin signal transduction.  
The chemical chaperone TUDCA was administered 4 hours prior to the commencement of 
one day feeding of HFru diet. The activity of JNK and insulin signal transduction was 
examined by immunobloting of phosphorylated-JNK (Threonine 183/ Tyrosine 185), -c-Jun 
(serine 63), -IRS1 (serine 307) (A) and -Akt (serine 473) (B) in whole cell lysate of liver. 
Hepatic triglyceride (TG) content (C). Liver membrane and cytosolic fractions were 
immunoblotted for PKCε (D). Liver homogenate was immunoblotted for microsomal TG 
transfer protein (MTTP) (E). Data are mean ± SE of 6-8 mice per group. * p<0.05 compared 
with CH; # p<0.05 compared with HFru. 
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Figure 3.8 Inhibition of IRE1 and JNK activity protect hepatic insulin signaling transduction. 
Betulin was administrated to the HFru-fed mice. Hepatic DNL was assessed by 
immunoblotting of: matured SBEBP-1c, ACC, FAS and SCD1 (A). The activity of IRE1 in 
the liver was determined by immunobloting of phosphorylated-IRE1 and spliced XBP1 in 
whole cell lysate (B). Hepatic triglyceride (TG) content (C). The activity of JNK and insulin 
signal transduction was examined by immunobloting of phosphorylated-JNK (Threonine 183/ 
Tyrosine 185 (D), -IRS1 (serine 307) (E) and -Akt (serine 473) (F) in whole cell lysate of 
liver. Representative blots are shown. Data are mean ± SE of 6-10 mice per group. * p<0.05 
compared with CH; # p<0.05 compared with HFru. 
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Figure 3.9 One day feeding of HFru diet impaired insulin action. 
ITT was performed in one day feeding of HFru -or CH-fed mice and insulin tolerance was 
assessed by reversed AUC (A). The phosphorylation of mTOR was examined by 
immunobloting (B). Representative blots are shown. Data are mean ± SE of 6 mice per group. 
** p<0.01 compared with CH; # p<0.05 compared with HFru. 
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3.4 Discussion  
The chapter investigated the mechanisms of UPR signaling and hepatic DNL in relation to the 
onset of insulin resistance in the liver. Our data demonstrated that both UPR signaling and 
DNL are rapidly initiated and persisted in response to HFru feeding. Using a one day feeding 
model, we found the IRE1 branch to be the first UPR arm to be activated in response to 
fructose. The activation of IRE1 was associated with impaired hepatic insulin signaling as 
indicated by reduced Akt phosphorylation, likely via increased JNK activity and serine 
phosphorylation of IRS1. The key role of IRE1-JNK in triggering HFru-induced hepatic 
insulin resistance was evidenced by the fact that inhibition of IRE1 activation by the chemical 
chaperone TUDCA was able to block the activation of JNK, IRS1 serine phosphorylation and 
preserve the insulin-stimulated phosphorylation of Akt.  
A growing body of evidence indicates that increased fructose intake is an important risk factor 
of metabolic syndrome including type 2 diabetes [215, 217, 221]. It has been shown in 
healthy subjects that ingestion of 20% fructose solution with meals can increase fasting blood 
glucose level and hepatic insulin resistance within 6 days [223]. Thus, the present study 
focused on the mechanisms of hepatic insulin resistance by feeding mice an HFru diet mimic 
the onset of fructose-induced insulin insensitivity in human. Dietary fructose is almost 
entirely metabolized in the liver [242] and converted into lipids via DNL unrestrained by 
cellular control, because it can bypass the feedback inhibition by ATP and citrate [218, 225]. 
If unutilized, the lipids synthesized from excess DNL will be channelled towards storage 
leading to hepatic steatosis which is considered to be closely related with insulin resistance. In 
addition to the potent stimulation of DNL, fructose is also able to induce UPR signaling in the 
liver [232].  
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UPR is demonstrated to contribute to insulin resistance [160, 193, 225] via IRE1/XBP1 [104, 
252] or PERK/eIF2α [169] branch. Furthermore, it has been suggested that UPR activation 
per se promotes DNL which subsequently leads to hepatic steatosis and impairs insulin 
signaling transduction [131, 160, 253]. It has been reported that  deletion of XBP1 in mice 
decreased DAG level, PKC activity in the liver and protected against hepatic insulin 
resistance in response to one week of fructose feeding without suppressing JNK activation 
[161]. Our recent study also showed that DAG accumulation in chronic fructose feeding 
associated with ER stress and insulin resistance in the liver along with glucose intolerance 
[232]. As hepatic insulin resistance is suggested to initiate whole-body insulin resistance 
[254], we set to investigate the involvement of cellular events (UPR and DNL) in the 
development of hepatic insulin resistance induced by HFru feeding. 
In order to establish a temporal relationship among these events, we compared the changes in 
PERK/elF2α and IRE1/XBP1 branches at various durations of HFru feeding ranging from 3 
days to 8 weeks. Consistent with our recent finding in mice fed with HFru diets for 1 week, 
we found that both PERK and IRE1 branches were activated at day 3 and maintained 
throughout the entire course of the experiment. This suggests that the activation of these two 
UPR branches was fully developed at this early stage and impaired insulin action was 
detected at 1 week. These effects sustained chronically to exert their long-term effects. 
To further dissect the changes of UPR pathways at the onset of hepatic insulin resistance, we 
examined the effects of one day feeding of HFru diet on these pathways in relation to insulin 
signal transduction and whole body metabolism. Interestingly, we found that one day of HFru 
diet is sufficient to impair hepatic insulin signaling without detectable glucose intolerance. 
The lack of glucose intolerance is explainable by the fact that at this stage insulin action in 
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muscle and adipose tissue were still intact, as indicated by the maintained Akt 
phosphorylation in response to insulin stimulation. Our findings are also consistent with a 
study in humans showing that a short-term (6 days) ingestion of fructose results in insulin 
resistance in the liver without obvious impact on insulin sensitivity in skeletal muscle [223]. 
Similar findings of hepatic insulin resistance prior to detectable whole-body insulin resistance 
have been observed previously [45, 255].  
Interestingly, the DNL pathway was significantly elevated by one day feeding of HFru diet in 
the liver and this was associated with the activation of only the IRE1 branch of the UPR 
signaling pathway, indicating that this arm rather than PERK branch may play a key role in 
the onset of hepatic insulin resistance in response to fructose feeding. Although IRE1/XBP1 is 
suggested to response to insulin [256], mice fed with HFru for 3 days and 8 weeks displayed 
ER stress accompanied by normal plasma insulin level (Table 1). This indicated that 
hyperinsulinemia was not the only trigger of IRE1 branch. IRE1 has been postulated to induce 
insulin resistance via two distinct mechanisms. Firstly, activated IRE1 results in the spicing of 
XBP1 leading to its maturation as an active transcription factor. The spliced XBP1 can 
upregulate key genes of fatty acid synthesis to increase de novo lipogenesis [158], leading to 
an accumulation of intermediate lipid metabolites including diacyglycerols (DAGs) [160, 
232]. Increased DAGs in the liver can recruit protein kinase C epsilon (PKCε) to the plasma 
membrane where it can inhibit the insulin signaling pathways via serine phosphorylation of 
insulin mediators like IRS [139, 161]. This subsequently leads to decreased insulin-stimulated 
phosphorylation of downstream signaling effectors such as Akt resulting in insulin resistance 
[136]. In the present study, we found a marked increase in key proteins of DNL and lipid 
accumulation in the liver. However, our results did not show any enrichment in the 
membrane-associated PKCε following the one day feeding of HFru diet. Therefore, we 
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examined whether or not DNL, lipid accumulation and impaired insulin signaling 
transduction may be prevented by blocking the activation of the IRE1/XBP1 pathway. Our 
results showed that the inhibition of IRE1 and the subsequent splicing of XBP1 by TUDCA 
completely prevented fructose-induced DNL. This indicates the suppression of XBP1 splicing 
downregulated hepatic DNL. However, PKC was not altered in response to decreased DNL, 
suggesting that the proposed DAG-PKCε mechanism is not an initiator of insulin resistance in 
the liver in this model.  
The other postulated mechanism linking IRE1 to insulin resistance is via the activation of 
JNK [104, 125]. It has been proposed that upon activation IRE1 recruits the adaptor protein, 
TNF receptor-associated factor 2 (TRAF2) to the surface of the ER membrane. The IRE1-
bound TRAF2 then activates the apoptosis-signaling kinase 1 (ASK1) leading to the 
phosphorylation and activation of JNK. JNK interferes with insulin signaling via 
serine/threonine phosphorylation of IRS proteins [257] and blunting its signal transduction to 
downstream molecules like Akt [258]. Consistent with these reports, there was a marked 
increase in JNK activity in the liver following one day feeding of HFru diet. As expected, the 
activated JNK was found to be associated with increased serine phosphorylation of IRS and 
impaired insulin signal transduction (decreased p-Akt in response to insulin stimulation). 
These data suggest that IRE1-mediated JNK activation initiate hepatic insulin resistance 
during acute HFru feeding. This mechanism is further supported by our subsequent study 
showing that inhibition of IRE1 with the chemical chaperone TUDCA was able to block the 
activation of JNK and serine phosphorylation of IRS1/2 and preserve insulin-stimulated 
phosphorylation of Akt in the liver during one day feeding of fructose. 
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Chronic administration of TUDCA has been reported to decrease hepatic triglyceride levels 
ob/ob mice [214]. It was puzzling to us in the first glance that hepatic TG content was not 
reduced by TUDCA. However, a recent report also showed the inability of TUDCA to reduce 
hepatic steatosis [259]. One possible reason for this might be that TUDCA was administered 
to mice in one dose only in our study.  To further investigate this discrepancy, we examined 
whether the lack of reduction in hepatic TG export may also be due to a simultaneous 
decrease in TG export from the liver by measuring the level of MTTP, a lipid transfer protein 
required for the assembly and secretion of VLDL-triglyceride by the liver [260]. The decrease 
in liver MTTP may explain, at least in part, the lack of change in hepatic triglyceride content 
in TUDCA-treated HFru-fed mice. As the knockout of liver IRE1α has been shown to 
decrease MTTP activity [179], it is likely that the down regulation of MTTP may result from 
the IRE1 activation by TUDCA. The protected hepatic insulin signaling transduction by 
TUDCA without reducing liver TG is consistent our interpretation that activate IRE1 can 
trigger insulin resistance via the activation of JNK independently.  
To further confirm the effect of IRE1/JNK on impaired insulin signaling transduction in the 
liver, we used betulin which was reported as a SREBP-1c inhibitor. Intriguingly, we found 
that despite the suppression of DNL, betulin could also reduce the p-IRE1 expression without 
affecting its downstream effector spliced-XBP1. However, another downstream target JNK 
which is catalyzed by the kinase activity of IRE1 showed a significant decrease. 
Simultaneously, impaired insulin signaling transduction was alleviated under betulin 
treatment. These results further support our hypothesis that JNK activation plays an important 
role in initiating hepatic insulin resistance.  
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In summary, the present study demonstrated that the IRE1-mediated JNK activation, rather 
than lipid accumulation, is a predominant trigger for the onset of hepatic insulin resistance 
induced by acute HFru feeding. However, this does not exclude the possibility that DNL-
induced lipid accumulation may contribute to the development of hepatic insulin resistance in 
the long term. Our findings suggest that the IRE1/XBP1 pathway may be a potential target for 
pharmacological treatment of insulin resistance in the liver induced by high fructose 
consumptions.  
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4.1 Introduction 
Liver is one of the most metabolically active and insulin responsive organs, regulating 
glucose homeostasis, lipid metabolism and protein synthesize [244]. Under normal conditions, 
insulin suppresses hepatic glucose production via glycogenolysis and gluconeogenesis, while 
promoting glucose storage in the form of glycogen to help control postprandial glucose level. 
However, the ability of insulin to shut down glucose production from the liver is diminished 
under the state of hepatic insulin resistance which in turn leads to the manifestation of 
hyperglycemia [243]. Although the pathogenesis of hepatic insulin resistance is likely to be 
multi-factorial, increased endoplasmic reticulum stress and an accumulation of lipids within 
the liver have been demonstrated to be important mechanisms [249, 261].  
Lipid accumulation in the liver or hepatic steatosis can lead to insulin resistance by interfering 
with the insulin signal transduction through lipid metabolites such as diacylglycerols and 
ceramide [261]. Hepatic steatosis can result from increased FA influx, elevated de novo 
lipogenesis and/or reduced fatty acid (FA) oxidation [244, 261]. In humans, elevated DNL 
from the increased consumption of sucrose is the predominant mechanism for the 
development of hepatic steatosis with fructose (breakdown product of sucrose) being the 
major culprit [225, 262].  
Recent studies in animal models [160, 214] have identified a possible role of ER stress in the 
development of hepatic insulin resistance during elevated DNL. When ER stress occurs, the 
ER mounts the UPR which involves the activation of three major branches of signal 
transducers: IRE1, PERK and ATF6 [102]. Activation of these canonical mechanisms is 
crucial for cellular adaption and resolution of ER stress. However, chronic activation of UPR 
signaling has been demonstrated to activate c-jun N-terminal kinase and IκB kinase. The 
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IRE1 branch of the UPR can activate JNK [104] and IKK [124] by forming a complex with 
the tumor-necrosis factor-α-receptor-associated factor 2 (TRAF2). Meanwhile, the 
PERK/eIF2a branch has also been reported to be capable of activating JNK [263]. As 
activated JNK [125, 214] and/or IKK [264] can directly serine/threonine phosphorylate 
insulin-receptor-substrate (IRS) leading to the inhibition of insulin signaling transduction, it 
has been suggested that JNK and IKK are the key molecules linking activated UPR and 
hepatic insulin resistance [258].  
A previous study from this laboratory reported that elevated DNL and insulin resistance in the 
liver of high fructose (HFru) fed mice is coupled to activation of the IRE1 and PERK 
branches of the UPR [193]. In the previous chapter, it was suggested that ER stress-related 
JNK activation plays predominant role in the development of hepatic insulin resistance. 
However, it is not clear whether ER stress remains as a key trigger of insulin resistance in the 
liver. Interestingly, hepatic DNL is increased by the activation of PPARα [265, 266] which 
has also been shown to reverse hepatic steatosis [267, 268]. Because ER stress is tightly 
associated with DNL, we hypothesized that treatment of HFru-fed mice with a PPARα agonist 
would activate both the IRE1 and PERK branches of the UPR while preventing hepatic 
steatosis. Under these conditions, we would then be able to interrogate the role of these two 
mechanisms (lipid accumulation or activated JNK/IKK) in hepatic insulin resistance in the 
face of increased ER stress. Our results revealed that accumulation of lipids namely DAGs, 
rather than the activation of JNK or IKK, is the key factor of hepatic insulin resistance during 
increased ER stress. Activation of PPARα with FENOFIBRATE is able to eliminate hepatic 
insulin resistance during HFru feeding by reducing DAG levels despite the presence of ER 
stress evidenced by the dual activation of the IRE1/XBP1 and PERK/eIF2α pathways. 
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4.2 Methods 
4.2.1 Animal Study 
The daily maintenance of animals was mentioned in details in the Chapter 2 (2.1). Fenofibrate 
(FB, Sigma-Aldrich, Australia) was supplemented to the animal by mixing into the diets at a 
concentration of 100 mg/kg/day. All experiments were approved by the Animal Ethics 
Committees of the RMIT University (#1012). 
Body weight and food intake were measured daily. The whole body metabolic rate was 
measured at 22ºC using an indirect calorimeter (Comprehensive Laboratory Animal 
Monitoring System, Columbus Instruments, OH, USA) as described in Chapter 2 between 5-8 
days after the administration of fenofibrate. Mice were fasted for 5-7 hours before being killed. 
Tissues of interest were collected and freeze-clamped immediately. Epididymal fat mass was 
weighed using an analytical balance. Liver triglycerides and plasma insulin measurements and 
GTT were performed. The details were described in Chapter 2(2.1.2, 2.1.3 and 0). For the 
assessment of insulin signaling in the liver, the mice were injected with insulin (2U/kg BW, ip) 
20 min before tissue collection. 
4.2.2 Measurement of hepatic FA oxidation DNL 
The details were described in 2.1.4.4 and 2.1.4.5. 
4.2.3 Citrate synthase and β3-hydroxyacyl-CoA dehydrogenase activity 
The details were described in 2.1.4.6. 
4.2.4 Western blotting 
The details were described in 2.3. 
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4.2.5 Analyses of hepatic lipids 
The details were described in 2.1.4.3. 
4.2.6 Statistical Analyses 
Data are presented as means ± SE. One-way analysis of variance was used for comparison of 
relevant groups. When significant variations were found, the Turkey-Kramer multiple 
comparisons test was applied. Differences at p<0.05 were considered to be statistically 
significant.  
 
4.3 Results 
4.3.1 FB treatment normalised HFru feeding induced adiposity and improved glucose 
intolerance 
HFru-feeding resulted in significant increases in calorie intake (~38%), the whole body 
oxygen consumption (VO2, ~ 8%) and the respiratory exchange ratio (RER), body weight 
gain (1.2 g) and adiposity (67% in epididymal fat mass, p<0.05) compared to untreated CH-
fed animal (CH-Veh) (Table 11). In CH-fed mice, fenofibrate treatment had no significant 
effects on body weight gain, adiposity, caloric intake or RER except for a 14% increase in 
VO2 (p<0.05 vs CH-Veh). In HFru-FB-fed mice, fenofibrate significantly (all p<0.05) 
increased VO2 (8%), reduced the RER and completely diminished HFru-induced body weight 
gain and adiposity. Fenofibrate lowered blood glucose and insulin levels in the HFru-fed mice 
(both p<0.01 HFru-FB), hence an improved HOMA-IR index. The untreated HFru-fed mice 
displayed glucose intolerance (Figure 4.1 A) compared to CH-Veh (Figure 4.1 A and B). 
Fenofibrate treatment completely normalized the glucose tolerance seen in the HFru-fed mice 
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to the levels of the CH-fed mice and reduced the requirement for plasma insulin level (Figure 
4.1 C). 
Table 11 Basal metabolic parameters of HFru-fed mice. 
 CH-Veh CH-FB  HFru-Veh  HFru-FB  
Body mass (g) 
   Day 0 
   Day 14 
 
27.0±0.4 
28.0±0.4 
 
27.5±0.4 
27.9±0.4 
 
28.0±0.5 
29.2±0.4b 
 
26.8±0.4 
22.2±0.6b,d,e 
EPI/BW 1.2±0.1 1.0±0.1 2.0±0.3b 0.7±0.1a,d 
Caloric intake (Kcal/kg.day) 411±6.6 436±12.3 571±9.7b.f 567±13.6b.f 
VO2 (l/kg.h) 3.23±0.07 3.70±0.14
a 3.50±0.03b  3.78±0.13b,c, e  
RER 0.93±0.01 0.92±0.01 0.97±0.01b 0.93±0.02 c 
Blood glucose (mM) 8.4±0.3 10.5±0.4b 10.2±0.5b 6.6±0.4b,d 
Plasma insulin (pg/ml)  203±23 91±16b 208±26 82±6d 
HOMA-IR  77.4±9.0 40.9±6.7a 96.3±16.8 23.3±2.2b,d 
Plasma triglyceride (M) 354±20 176±10b 264±16b 260±32b 
Male C57BL/6J male mice were fed either a CH or fructose-rich diet (HFru) for 2 weeks with 
or without the supplementation of a PPARα agonist, fenofibrate (FB, 100 mg/kg/day). The 
data for whole body oxygen consumption (VO2) and respiratory exchange ratio (RER) were 
the average values of 24 hours of measurement after 1 week of fenofibrate administration. 
HOMA-IR was calculated using the fasting blood glucose (mmol/L) multiplying by the 
fasting Insulin (mU/L) divided by 22.5. Data are means ± SE of 8–12 mice per group. a 
p<0.05, b p<0.01 vs untreated CH-fed mice (CH-Veh); c p<0.05, d p<0.001 vs untreated 
HFru-fed mice (HFru-Veh); e p<0.001 vs fenofibrate treated chow-fed mice (CH-FB). 
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Figure 4.1 Effects of FB treatment on glucose tolerance. 
Male C57BL/6J mice were fed a high fructose (HFru) diet with or without the 
supplementation of fenofibrate (FB, 100 mg/kg/day) as compared to a standard laboratory 
chow diet (CH). The experiments were performed after two weeks of chow (CH, ●), chow 
with fenofibrate (CH-FB, ○), high fructose (HFru, ■) or high fructose with fenofibrate (HFru-
FB, □) feeding. (A) Glucose tolerance test (GTT) was performed with an injection of glucose 
(2.5 g/kg, ip) after 5-7 hours of fasting. (B) iAUC, incremental area under the curve for blood 
glucose level. (C) Plasma insulin level between 30-60 min of GTT. Data was means ± SE, 8-
12 mice per group. * p < 0.05; †† p < 0.01 of the compared groups. 
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4.3.2 FB treatment restored hepatic insulin signal transduction in HFru-fed mice 
In skeletal muscle, insulin stimulated phosphorylation of Akt (all p<0.001 vs corresponding 
basal) was unaltered by diet or fenofibrate treatment (Figure 4.2 C). In contrast, HFru feeding 
blunted insulin-stimulated phosphorylation of Akt (by 53%, p<0.01 vs CH) and its 
downstream target GSK3β (by 60%, p<0.001 vs CH) in the liver both of which were fully 
restored by treatment with fenofibrate (Figure 4.2 A and B). This indicated HFru feeding 
resulted in impairment of hepatic insulin signaling and that treatment of fenofibrate was 
effective in restoring hepatic insulin sensitivity. 
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Figure 4.2 Effects of fenofibrate treatment on hepatic insulin signal transduction.  
After two weeks of feeding, animals were fasted for 5-7 hours before tissue collection. Liver 
homogenate were prepared for immunoblotting: (A) representative blots of phosphorylated- 
and total-Akt (Ser473) with densitometry in the liver, (B) representative blots of 
phosphorylated- and total- GSK3β (Ser219) with densitometry in the liver in response to a 
bolus of insulin stimulation (2U/kg, ip).  (C) Muscle homogenate were prepared for 
immunoblotting. The representative blots for phosphorylated- and total- Akt (Ser473) and 
GSK3β (Ser219) with densitometry in the muscle in response to a bolus of insulin stimulation 
(2U/kg, ip). Each lane represents a single mouse. Data are mean ± SE of 8 mice per group. All 
insulin stimulated groups reached statistical significance of p < 0.01 compared to their 
corresponding basal groups unless otherwise indicated. ** p < 0.01; †† p < 0.001 of the 
compared groups. 
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4.3.3 FB treatment normalised hepatic lipid accumulation 
Lipid accumulation in the liver (i.e. hepatic steatosis) is believed to be closely linked to 
insulin resistance [244]; we hence examined the effects of fenofibrate treatment on hepatic 
lipid content. As expected, chronic HFru feeding induced a marked increase in hepatic 
triglyceride (TG) levels (2.7-fold, p<0.01 vs CH) which was ameliorated by the treatment of 
fenofibrate (Figure 4.3 A), while the fasting plasma TG levels were similar between the HFru-
Veh and HFru-FB group (Table 11). In agreement with an increased TG levels, hepatic DAG 
content in HFru-fed mice was also elevated by 53% (p<0.05 vs CH) which was normalised by 
the treatment with fenofibrate (Figure 4.3 B). Total content of hepatic ceramide was 
attenuated by 57% (p<0.001 vs CH) by HFru-feeding, but was restored (ns. vs CH and CH-
FB) by the treatment of fenofibrate (Figure 4.3 C). These data suggest a role of DAG in the 
hepatic insulin resistance resulting from prolonged HFru feeding.  
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Figure 4.3 Effects of FB treatment on hepatic lipid content.  
After two weeks of feeding, animals were fasted for 5-7 hours before tissue collection. Liver 
homogenate were extracted for the assessment of total TG (A), DAG (B) and ceramide (C) 
content. Data are mean ± SE of 8 mice per group. ** p < 0.01; †† p < 0.001 of the compared 
groups. 
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4.3.4 FB treatment increased hepatic fat oxidation under HFru-feeding 
As enhanced FA oxidation is one of the key events resulting from the activation of PPARα by 
FB in the liver [198, 202, 269], we measured molecular markers of oxidative capacity in the 
livers of mice. The expression of peroxisomal acyl-Coenzyme A oxidase-1 (ACOX1), a direct 
downstream effector of PPARα activation, which catalyzes the first step of peroxisomal -
oxidation of FAs [203], was markedly up-regulated in response to the treatment with 
fenofibrate (Figure 4.4 A). Moreover, the phosphorylation of ACC which regulates the 
mitochondrial β-oxidation of FAs was markedly elevated (8-fold, p<0.001 vs CH-Veh and 
HFru-Veh) in response to fenofibrate treatment in the liver of the HFru-fed mice (Figure 4.4 
B). In line with an increased oxidative capacity, the activity of β-HAD, which catalyzes the 
third step of mitochondrial β-oxidation, was augmented by 2.4-fold (p<0.01 vs CH-Veh and 
HFru-Veh) with fenofibrate treatment in the HFru-fed mice (Figure 4.4 C). The activity of 
citrate synthase was significantly enhanced (by 19%, p<0.01 vs CH) under HFru feeding 
independent of PPARα activation (Figure 4.4 D), indicating PPARα activation specifically 
enhances the oxidative capacity of the liver without affecting mitochondrial content under 
HFru feeding. Hepatic FA oxidation was increased (~60%) by the treatment of fenofibrate in 
the HFru-fed mice and this was due to an increase in the component resistant to the inhibition 
by etomoxir (Figure 4.4 E). 
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Figure 4.4 Effects of FB treatment on key enzymes of FA oxidation.  
After two weeks of feeding, animals were fasted for 5-7 hours before tissue collection and 
liver homogenates were immunoblotted for key enzymes related to oxidative capacity: 
representative blots of ACOX1 (A), phosphorylated-ACC (Ser79) (B), the specific activities 
of β-HAD (C), and citrate synthase (D). Each lane represents a single mouse. Data are mean ± 
SE of 10 mice per group. (E) Hepatic fatty acid (FA) oxidation was measured in separate liver 
homogenates using 14C-palmitate as a substrate in the presence or absence of 0.02 mM 
etomoxir (detail methods can be found in the supplementary information). Data are mean ± 
SE of 6-8 mice per group. * p < 0.05; ** p < 0.01 vs CH; † p < 0.05, †† p < 0.001 of the 
compared groups. 
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4.3.5 FB treatment triggered the activation of UPR pathways in the liver 
Having established that treatment of fenofibrate was effective in eliminating hepatic lipid 
accumulation and restoring insulin signaling, we next sought to examine its effects on the 
three major UPR pathways.  The phosphorylation of IRE1 (Figure 4.5 A), spliced form of 
XBP1 (sXBP1; Figure 4.5 B), phosphorylation of PERK and eIF2α (Figure 4.5 C and D), as 
well as the expression CHOP (Figure 4.5 E) were markedly enhanced by PPARα activation 
regardless of the feeding conditions. In addition, the expression of GADD34, a well-
characterized phosphatase of eIF2α [102] was concomitantly down-regulated in response to 
PPARα activation (Figure 4.5 F). As expected, HFru feeding significantly increased the 
phosphorylated form of IRE1 (Figure 5 A, p<0.05 vs CH) and eIF2α (Figure 4.5 D, p<0.01 vs 
CH). No changes were detected in the maturation of activating transcription factor 6 (ATF6) 
as a result of HFru-feeding or fenofibrate treatment (Figure 4.5 G).  
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Figure 4.5 Effects of FB treatment on hepatic UPR signaling. 
After two weeks of feeding, animals were fasted for 5-7 hours before tissue collection and 
liver homogenates were immunoblotted for markers of ER stress: representative blots of 
phosphorylated-IRE1 (Ser724) (A), spliced form of XBP1 (B), phosphorylated-PERK 
(Thr980) (C), phosphorylated-eIF2α (Ser51) (D), CHOP (E), GADD34 (F) and ATF6 (G) 
with densitometry. Each lane represents a single mouse. Data are mean ± SE from 8 to 10 
mice per group. * p < 0.01 vs CH, ††  p < 0.01 of the compared groups. 
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4.3.6 FB-induced UPR signaling was accompanied by an enhanced DNL 
As both activation of PPARα [198] and UPR signaling [160] can promote DNL in the liver 
via the action of sterol regulatory element-binding protein-1c (SREBP1c) [157], we hence 
examined the expression of SREBP1c and key enzymes involve in this process. Our western 
blotting analysis revealed up-regulations of the mature form of SREBP1c (mSREBP1c, 3-fold, 
p<0.05 vs CH-Veh), ACC (3.5-fold, p<0.01 vs CH-Veh), FAS (2.5-fold, p<0.001 vs CH) and 
SCD1 (14.5-fold, p<0.01 vs CH-Veh) in the liver of the HFru-fed mice (Figure 4.6A-D). 
PPARα activation in the CH-fed mice stimulated the expression of mSREBP1c, ACC, FAS 
and SCD1 to levels comparable to that of the HFru-fed mice. PPARα activation in 
conjunction with HFru-feeding elicited a further increase in the expression of mSREBP1c (6-
fold) and SCD1 (38-fold, both p<0.001 vs HFru-Veh), but not ACC (2.8-fold, p<0.01 vs CH) 
nor FAS (2.9-fold, p<0.001 vs CH, both not different vs HFru-Veh). Consitent with the up-
regulated lipogenic enzymes, hepatic DNL was significantly increased (~38 %) by PPARα 
activation in CH-fed mice and this increase was maintained in fenofibrate treated HFru-fed 
mice (Figure 4.6 E). These data suggested the fenofibrate-induced modulation of UPR 
signaling may enhance the lipogenic capacity of liver independent of the effects of dietary 
fructose. 
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Figure 4.6 Effects of FB treatment on hepatic DNL.  
After two weeks of feeding, animals were fasted for 5-7 hours before tissue collection and 
liver homogenates were immunoblotted for key enzymes related to lipogenic capacity: 
representative blots of the matured form of SREBP1c (mSREBP1c) (A), ACC (B), FAS (C) 
and SCD1 (D) with densitometry. Data are mean ± SE of 10 mice per group. (E) Hepatic 
DNL was measured by the incorporation of [3H]-H2O into hepatic triglyceride (detail 
methods can be found in the supplementary information). Data are mean ± SE of 6 to 8 mice 
per group. * p < 0.05 vs CH; ** p < 0.01; †† p < 0.001 of the compared groups. 
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4.3.7 The downstream effects of the FB -induced UPR signaling 
Production of deleterious lipids (lipotoxicity) via DNL and activation of serine/threonine 
kinases are key consequences of UPR signaling which interferes with insulin signal 
transduction at various points [258]. As shown in Figure 3B, treatment of fenofibrate was able 
to correct the elevated DAG content induced by HFru-feeding. Meanwhile, activation of JNK 
and IKK are well-demonstrated consequences of UPR signaling resulting in the impairment of 
insulin signal transduction [249]. HFru feeding did not result in a significant induction of JNK 
(Figure 4.7 A) or IKK (Figure 4.7 B), and the expression of IκBα (Figure 4.7 C), the 
downstream target of IKK [270], remained unaffected which is consistent with our previous 
observation [193]. Despite the significant induction of the two specific arms of UPR pathways, 
the phosphorylation status of these kinases remained unaffected in response to fenofibrate 
treatment (Figure 4.7 A to C). These data suggested PPARα activation is effective in 
eliminating lipotoxicity and that the fenofibrate-induced UPR signaling did not result in the 
activation of these stress kinases. 
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Figure 4.7 Effects of FB treatment on JNK and IKK activation.  
After two weeks of feeding, animals were fasted for 5-7 hours before tissue collection and 
liver homogenates were immunoblotted for evidence of JNK and IKK activation:  
representative blots of phosphorylated-JNK (A), phosphorylated-IKK (B), IκBα (C). Data are 
mean ± SE of 8 mice per group. n.s. denotes no statistical differences. 
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Supplementary data: 
 
Supplementary Figure 1.Densitometry of insulin-stimulated Akt phosphorylation in muscle. 
After two weeks of feeding, animals were fasted for 5-7 hours before tissue collection and red 
quadriceps muscle homogenates were immunoblotted for phosphorylated-Akt (Ser473) in 
response to a bolus of insulin stimulation (2U/kg, ip). Data are mean ± SE from 8 to 10 mice 
per group. All insulin stimulated samples reached statistical significance of p < 0.01 
comparedto that of the non-stimulated. No significant difference was observed among the 
stimulated groups. 
 
Supplementary Figure 2. Effects of FB treatment on ATF6. After two weeks of feeding, 
animals were fasted for 5-7 hours before tissue collection and liver homogenates were 
immunoblotted for ATF6. Representative blot is shown with densitometry. Eachlane 
represents a single mouse. Data are mean ± SE from 8 to 10 mice per group. n.s. denotes no 
statistical differences.  
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4.4 Discussion  
In this chapter, we established a hepatic ER stress model independent of lipid accumulation in 
the liver with the administration of PPARα activator, fenofibrate (FB), in HFru-fed mice. This 
model enabled us to examine the effects of ER stress on hepatic insulin sensitivity devoid of 
the influence of hepatic steatosis. The results revealed that PPARα activation completely 
eliminates HFru-induced hepatic steatosis and insulin resistance without altering JNK and 
IKK in the face of marked dual activation of the IRE1/XBP1 and PERK/eIF2α branches of 
the UPR pathways. These findings indicate that hepatic steatosis, but not JNK, is required for 
ER stress to cause insulin resistance. To the best of our knowledge, this is the first report to 
demonstrate that PPARα activation induces UPR signaling while ameliorating hepatic insulin 
resistance. 
PPARα is a key transcriptional regulator for lipid metabolism and it can be endogenously 
activated by FAs, as well as pharmacologically by agonists like fenofibrate [265]. Fenofibrate 
is a specific agonist of PPARα commonly used to treat dyslipidaemia and 
hypercholesterolemia in humans [200]. These beneficial effects are attributed to the PPARα-
driven peroxisomal and mitochondrial β-oxidation and microsomal ω-oxidation of FA with 
the liver being a major site of action [271]. The results showed that fenofibrate treatment was 
effective in activating PPARα in vivo as evidenced by the increased expression of ACOX1 
(also known as palmitoyl-CoA oxidase) [272] which is a direct target of PPARα. The 
concomitant increase in VO2 and the induction of the phosphorylated form of ACC and β-
HAD activity along with the augmented FA oxidation in the liver are indicative of an 
enhanced oxidative capacity and energy expenditure which are consistent with the reported 
effects of PPARα activation [271, 273]. In line with the upregulation of ACOX1 expression, 
fenofibrate-induced increase in hepatic FA oxidation can be attributed to the enhanced 
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peroxisomal oxidation that is not inhabitable by etomoxir which blocks the entry of long-
chain FAs into mitochondria for oxidation.  It has been reported that peroxisomal oxidation 
break down (very) long-chain FAs into medium and short chain FAs further oxidation in 
mitochondria [273]. Unlike long chain FAs, the short- and medium-chain FAs do not rely on 
CPT1 to enter the mitochondria [273] which may explain, at least in part, the increased 
oxygen consumption as observed at the whole body level. It is likely that the reduced body 
weight and adiposity observed only in fenofibrate treated HFru-fed mice is due to the 
enhanced peroxisomal oxidation which was not evident in treated CH-fed mice. 
The restored HOMA-IR resulting from the lowered fasting blood glucose and insulin levels, 
together with the restored hepatic insulin signal transduction in the HFru-fed mice by 
fenofibrate are suggestive of improved insulin sensitivity in these mice. This interpretation is 
also supported by the striking reduction in insulin secretion in fenofibrate treated chow fed 
mice while maintaining unaltered glucose clearance. The insulin-sensitising effect of 
fenofibrate observed in the present study is consistent with our previous report of the insulin 
sensitizing effect of PPARα activation in high fat fed insulin resistant rats as determined by 
the hyperinsulinemic-euglycemic clamp [274]. 
The ER plays a pivotal role in protein processing to maintain cellular homeostasis under 
physiological conditions through the three canonical branches of UPR signaling pathways: 
PERK/elF2α, IRE1/XBP1 and ATF6. The initiating proteins PERK, IRE and ATF6 all have 
sensors facing the ER lumen and they can be activated under ER stress such as the 
accumulation of misfolded proteins [102, 258]. Activated IRE1/XBP1 pathway has been 
suggested to promote DNL in the liver leading to the production of lipids [160, 261]. In 
addition, both IRE1 [104] and PERK [163] have been suggested to activate JNK and IKK. 
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These mechanisms, acting in concert or alone, are sufficient to impair insulin signaling in the 
liver. However, it has been difficult to separate the effect of activated UPR pathways on 
hepatic insulin signaling in vivo from the influence of lipid accumulation. Moreover, 
fenofibrate is a lipid-lowering drug commonly used in humans and fructose consumption is 
closely related to the epidemic of obesity and fatty liver [262, 275]. Thus, the approach of 
fenofibrate administration to insulin resistant mice induced by HFru feeding not only allowed 
us to dissect this integral relationship, but also provided new insight into the mechanisms 
relevant to the conditions in humans. 
Both DAG and ceramide are key lipid intermediates linking hepatic steatosis to insulin 
resistance [261]. Our results showed that liver DAG content was higher in HFru-fed mice (as 
a result of increased DNL) and this is consistent with a previous report in HFru-fed mice 
[161]. DAG can activate protein kinases C ε (PKCε) which in turn phosphorylates the insulin 
receptor substrate 1 (IRS1) at serine 307 to disrupt tyrosine phosphorylation of IRS1 [276]. 
This could blunt IRS-mediated phosphorylation of its downstream signaling target such as 
Akt [140]. While maintaining elevated DNL (as indicated by mSREBP1c, ACC, FAS, SCD1, 
and the incorporation of [3H]-H2O into triglyceride) induced by HFru diet, fenofibrate was 
able to outpace DNL by a much greater effect to accelerate FA oxidation (as indicated by the 
14-16% increase in VO2, 3.9-fold, 8-fold and 2.1-fold increases in ACOX1, pACC and β-
HAD, respectively), hence eliminating the accumulation of TG and DAG. This may offer an 
explanation towards the improved insulin signaling by fenofibrate. In HFru-fed rat, hepatic 
ceramide has been reported to be increased [239] and this lipid metabolite can suppress the 
phosphorylation of Akt via protein phosphatase 2A [135, 146]. In the present study ceramide 
is unlikely to be a contributor for the blunted insulin signaling because its level in HFru-FB 
mice was similar to the level in chow-fed mice. However, the precise role of ceramide 
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requires further investigation as the cellular location may be a key determinant of its effect on 
insulin sensitivity [277]. 
The other key mechanism for ER stress induced insulin resistance is the activation of JNK and 
associated stress kinases. Sustained ER stress has been shown to cause hepatic insulin 
resistance via the induction of JNK and IKK [125, 214] and all three canonical arms of the 
UPR pathways are capable of activating JNK and IKK signaling under conditions of severe 
ER stress [249]. Consistent with our previous finding [193] HFru feeding was accompanied 
by the presence of ER stress. Despite further activation of the IRE1/XBP1 and PERK/eIF2α 
signaling by the activation of PPARα with fenofibrate, the unaltered phosphorylation of JNK 
and IKK or Iκ-B content argues against their role in the improved insulin signaling properties 
in the liver.  In addition, cellular ceramide is also known to be implicated in the up-regulation 
of IKK and JNK [146]. The fact that neither ceramide nor these stress-related kinases were 
up-regulated by fenofibrate is also consistent with the interpretation of the reduction in DAGs 
as a more likely mechanism for the alleviation of hepatic insulin resistance by the activation 
of PPARα. Of interest, Jurczak et al. [161] has recently demonstrated alleviation of hepatic 
DAG accumulation in mice with conditional knockout of XBP1. The absence of XBP1 can 
reverse fructose-induced insulin resistance despite the presence of ER stress and JNK 
activation which supports the notion of DAGs being the major culprit for hepatic insulin 
resistance induced by HFru feeding. 
It has been suggested that mild ER stress may enhance hepatic insulin signaling and protect 
against lipotoxicity via the induction of an adaptive UPR [278]. Mice carrying liver specific 
deletion of IRE1 displayed overt steatosis when challenged with ER stress inducers [99], 
while genetic ablation of either ER stress-sensing or ER quality control molecules also 
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resulted in the development of hepatic steatosis [173]. Furthermore, IRE1 has been reported 
capable of repressing the expression of key metabolic transcriptional regulators, including 
CCAAT/enhancer-binding protein (C/EBP) β, C/EBPδ, PPARγ, and enzymes involved in 
triglyceride biosynthesize [173], which suggests that UPR might be an important mechanism 
for mitigating steatosis. The results in the this chapter highlight the need for further 
investigation to examine whether specific UPR signaling may in fact contribute to the 
PPARα-mediated effects on insulin sensitivity.  
Although attenuated body weight gain in the HFru-fed mice induced by fenofibrate may 
confound our interpretation at the first glance, the pivotal role of lipids (but not the activated 
UPR per se) in ER stress associated insulin resistance is also demonstrated in CH-FB fed 
mice without body weight change (compared to CH-fed mice). Despite similar dual activation 
of both IRE1/XBP1 and PERK/eIF2α pathways in the fenofibrate-treated CH-fed mice, 
insulin-mediated phosphorylation of Akt and GSK3β remained intact in the absence of lipid 
accumulation. This interpretation is consistent with a previous study showing reduced liver 
lipids as the underlying mechanism of improved hepatic insulin sensitivity during body 
weight loss in patients with type 2 diabetes [279].  
In summary, these results indicated that lipid (particularly DAG) accumulation, but not the 
activation of JNK or IKK, is required for ER stress to cause hepatic insulin resistance and 
glucose intolerance during HFru consumption. Increased peroxisomal oxidation of FAs and 
energy expenditure are likely to underpin the observed reduction in hepatosteatosis and 
insulin resistance in fenofibrate-treated HFru-fed mice despite marked increases in UPR 
signaling and de novo lipogenesis. Therefore, activation of PPARα with fenofibrate 
ameliorates HFru-induced hepatic insulin resistance by eliminating lipid deposition by 
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blocking its link with ER (Figure 4.8). This chapter also suggests a need for further 
investigation as to whether activation of specific UPR pathways may in fact contribute to the 
therapeutic effects of fibrate drugs which are commonly used in humans.  
 
Figure 4.8 Illustration of PPARα -mediated effects on ER stress, lipid metabolism, and insulin 
sensitivity in the liver. 
HFru feeding accentuates the accumulation of TG and DAG in the liver through the induction 
of DNL. The accumulation of these lipid metabolites attenuates normal insulin signal 
transduction leading to hepatic insulin resistance, resulting in the reduction of glucose 
tolerance. PPARα activation by fenofibrate may also directly stimulate lipogenesis, which 
may involve the signaling of specific arms of the UPR pathways. However, the predominant 
effect of potentiated oxidative capacity (primarily peroxisomal oxidation) driven by PPARα is 
capable of eliminating lipid accumulation, thus overcoming fructose-induced hepatic insulin 
resistance (IR) and glucose intolerance. 
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5.1 Introduction 
The role of either ER stress and lipid accumulation in the initial insulin resistance in the liver 
has been discussed in Chapter Chapter 3 and Chapter Chapter 4. The mechanisms of ER stress 
and lipid accumulation leading to hepatic insulin resistance were different at different stage of 
insulin resistance. According to previous study, lipid accumulation per se appeared to be 
insufficient to induce insulin resistance in the liver at early stage. However, it becomes a 
predominant factor to exacerbate insulin resistance in long term HFru-fed mice. Relatively, 
the effect of JNK activation on hepatic insulin resistance reduced. This result is consistent 
with current literature report [162]. These changes led us to explore the relationship between 
ER stress and lipid accumulation. Although most current reports suggested that lipid 
accumulation induce ER stress (details in 1.6.2), ER is a critical organelle for lipid processing 
where many enzymes involved in intermediary and complex lipid metabolism reside [258]. 
Thus, UPR is considered to be able to regulate the lipid processing. Indeed, some studies 
indicated that enhanced ER stress could also upregulate lipid accumulation (details in 1.6.1).  
However, the relationship between ER stress and lipid metabolism remains unclear in fructose 
over consumption model.  
The study in this chapter utilized fructose to induce ER stress in cultured cells, aimed to 
mimic the high fructose feeding model in animals. According to the results from previous 
studies, the suppression of ER stress by TUDCA led to decrease of lipogenesis and lipid 
accumulation in the liver. On the other hand, the downregulation of lipogenesis by betulin 
administration resulted in a significant reduction of IRE1. To further confirm the sequence of 
the occurrence of ER stress and DNL, we treat cells with betulin which has been used in 
previous study.  
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Our data showed that fructose treatment enhanced lipogenic proteins (tACC, FAS and SCD1). 
The triglyceride level also increased in fructose-treated cells. Both IRE1 and eIF2α were 
stimulated significantly by fructose administration. Betulin administration suppressed tACC 
and FAS but not SCD1. Consistent with what we observed in the animal, betulin treatment 
did not reduce the TG level. Interestingly, betulin failed to inhibit p-IRE1 as well as p-eIF2α. 
All these results suggested that lipid may not be a critical cause of ER stress in fructose-
overconsumption model.  
 
5.2 Methods  
5.2.1 Cell culture 
The details were described in 2.2.1. 
5.2.2 Cell treatment 
FAO (differentiated rat liver cell) and HepG2 (human liver carcinoma cell) cells were seeded 
into 12- well plates when the confluence reached 75% in the flask. The cells were incubated 
in the DMEM medium (Cat. 11885) with 1% Penicillin-Streptomycin-Glutamine (PSG) for 
24 hours. Medium was then changed into the “cultured mediums” with 1% PSG. Cells were 
cultured with these mediums for 24 hours and were harvested for following analysis.  
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Table 12 Cultured mediums. 
 Glucose FBS Fructose 
Serum-control 10 mM 10% - 
Control  10 mM - - 
Serum-Fructose 10 mM 10% 25 mM 
Fructose 10 mM - 25 mM 
Serum-High 
glucose 
50 mM 10% - 
High glucose 50 mM - - 
 
5.2.3 Protein extraction from cells 
Medium was removed from the wells and cells were rinsed with PBS for twice and scraped 
immediately following the addition of HES buffer. The cell lysate was transferred into a 1.5 
ml microcentrifuge tube. Syringe needles were used to break down cells. The lysate was 
centrifuged at 3000 rpm for 10 min. The supernatant was removed and the pellet was 
suspended with 100 μl HES buffer. The lysate was then applied for protein assay or stored at -
80 oC. 
Table 13 HES buffer. 
Stock Fresh 
HEPES 5 mM NaF 10 mM 
EDTA 0.5 mM PMSF 1 mM 
Chapter 5  
 
117 
 
Stock Fresh 
sucrose 250 mM 
protease/phosphatase 
inhibitors 
10 ul/ml 
 
 
5.2.4 Western blotting 
The details were described in 2.3. 
 
5.2.5 Statistical Analyses 
Data are presented as means ± SE. One-way analysis of variance was used for comparison of 
relevant groups. When significant variations were found, the Tukey-Kramer multiple 
comparisons test was applied. Differences at p<0.05 were considered to be statistically 
significant.  
 
5.3 Results 
5.3.1 Establishment of cell model 
FAO cells are a differentiated rat liver cell line derived from rat H4IIIE hepatoma cells. 
HepG2 is a human liver carcinoma cell line. To identify which cell line fitted with our model 
and what kind of cultured medium was suitable for the hypothesis, both cell lines were 
cultured with several different mediums. The result showed that with respect to lipogenesis, 
FAO cells exhibited a high level of lipogenesis in response to the fructose media indicated by 
significant increase in ACC and FAS (Figure 5.1 A, B). In contrast, FAO cells which were 
treated with serum-control, serum-fructose, serum-high glucose and high glucose medium did 
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not show an increase in lipogenesis as shown by no difference in either ACC or FAS. HepG2 
showed significant upregulation of ACC when treated with either serum-control or fructose 
medium (Figure 5.1 A). Relatively, the level of FAS did not exhibit any significant changes 
between groups (Figure 5.1 B). However, when treated with 10 mM glucose and 25 mM 
fructose, FAS tended to be upregulated, but was not significant (p=0.068 vs control, t-test).  
Regarding ER stress response, FAO cells failed to show any enhancement of phosphorylation 
of IRE1 regardless of media condition used (Figure 5.1 C). However, p-eIF2α modestly 
increased when cells were treated with 50mM glucose in the presence or absence of FBS 
(Figure 5.1 D). HepG2 cells, alternatively, exhibited activation of both p-IRE1 and p-eIF2α in 
response to most media conditions (Figure 5.1 C, D).  
According to the previous data and the hypothesis, HepG2 appeared to be an appropriate 
candidate to achieve the requirement of induction of both ER stress and de novo lipogenesis. 
Meanwhile, though HepG2 cells were able to response to several alternative mediums, 
fructose became the priority as it has been used in our previous study in vivo. In the medium 
with additional fructose, the presence of FBS appeared to have negative effects on lipogenesis 
proved by non-significant augments in both ACC and FAS expression. Hence we select 
HepG2 as the cell line and the medium which contains 10mM glucose and 25mM fructose 
without FBS (fructose media) as the cultured medium for the following studies. 
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Figure 5.1 Lipogenesis and ER stress in FAO or HepG2 in different mediums. 
FAO or HepG2 cells were incubated as described in the methods. Cell homogenates were 
immunoblotted for evidence of ACC (A), FAS (B), p-IRE1 (C) and p-eIF2α (D). Data are 
mean ± SE of 3-4 replicates. * p <0.05, ** p <0.01 for compared group. L, concentration was 
25mM. H, concentration was 50mM.  
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5.3.2 Betulin treatment suppressed lipogenesis 
The results suggest that the lipogenesis was augmented in response to 25 mM fructose 
treatment. The expression of ACC was upregulated (p=0.063) (Figure 5.2 A). FAS and SCD1 
(Figure 5.2 B, C) which were other two critical lipogenic enzymes were significantly 
increased. However, the extent of stimulation of ACC (20%) and FAS (21%) (Figure 5.2 A, B) 
with fructose induced lipogenesis in cells was not as strong as in animals. SCD1 was 
upregulated for more than 3-fold change in fructose treated cells (Figure 5.2 C). Betulin 
treatment in fructose media reduced the levels of both ACC and FAS while the level of SCD1 
remained as high as in fructose treatment (Figure 5.2 A, B). The expressions of both enzymes 
were reduced to the level that was approximately 50% of the control group. However, the 
intracellular TG content was not reduced by betulin administration (Figure 5.2 D). These data 
suggest that fructose-induced lipogenesis in HepG2 cells was reduced at least partially by 
betulin. 
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Figure 5.2 Suppression of ACC and FAS but not SCD1 by betulin.  
HepG2 cells were incubated in fructose media in the presence or absence of betulin (10μM) 
for 24 hours. Cell homogenates were immunoblotted for evidence of ACC (A), FAS (B) and 
SCD1 (C). Cell triglyceride (TG) content (D) was determined following 24 hours incubation. 
Data are mean ± SE of 3-4 replicates. * p <0.05, ** p <0.01 for control group, ## p<0.01 for 
fructose group. 
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5.3.3 Betulin treatment did not moderate ER stress 
Protein overloaded or excess lipid accumulation has been suggested to trigger ER stress in 
some cultured cell types [189]. High fructose promoted lipogenesis, leading to an augment of 
expression of lipogenic enzymes. Meanwhile, exacerbated ER stress was detected as shown 
by the significant elevation of p-IRE1 (1.8-fold increasing) and p-eIF2α (2-fold) (Figure 5.3 A, 
B). In the presence of betulin, in contrast, neither p-IRE1 nor p-eIF2α was affected (Figure 
5.3 A, B).  
 
 
 
Figure 5.3 Betulin did not have negative effects on p-IRE1 or p-eIF2α.  
HepG2 cells were incubated in 25mM glucose DEME with 25mM fructose in the presence or 
absence of betulin (10μM) for 24 hours. Cell homogenates were immunoblotted for evidence 
of p-IRE1 (A) and p-eIF2α (B). Data are mean ± SE of 3-4 replicates. * p <0.05, ** p <0.01; 
of compared group. 
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5.4 Discussion 
The relationship between ER stress/UPR and lipid accumulation has previously been 
considered as bidirectional in different models [160, 172, 173] [186, 187]. In the current study, 
ER stress was induced by fructose rather than fatty acid (palmitate), or other pharmacological 
inducers such as tunicamycin or thapsigargin [170]. This study investigated the interaction 
between ER stress and DNL under the challenge of high fructose. Our data demonstrated that 
both ER stress-initiated UPR signaling and DNL were magnified in response to fructose 
treatment. Different to results that presented in the animal model, both IRE1 and PERK 
branches were enhanced. The activation of both the signaling arms was accompanied by 
augment of lipogenesis which was consistent with the result that we found in the animal 
model. The relationship between activated UPR and lipogenesis was investigated using 
betulin administration, in an attempt to block lipogenesis. With the presence of betulin, 
lipogenic enzymes were significantly diminished. However, the magnified phosphorylation of 
IRE1 and eIF2α induced by high fructose were not altered by betulin, suggesting that 
increasing lipogenesis did not contribute to the activation of the IRE1 and PERK branches of 
the UPR under the condition of fructose oversupply.  
ER stress can be induced by endogenous factors or pharmacological chemicals. Lipid, 
especially saturated fatty acid, is considered to be an effective trigger of endogenous factor of 
chronic ER stress. The link between aberrant lipid metabolism and disturbance of ER function 
in the liver might be a disruption of calcium homeostasis. Suneng and his colleagues 
investigated the alterations of both protein and lipid during ER stress in ob/ob mice. SERCA 
is a group of calcium ATPase which transfers Ca2+ from the cell cytosol to the lumen. Their 
results demonstrated that increased SERCA expression restored calcium homeostasis and 
caused significant reductions in p-IRE1 and CHOP and a slight suppression of p-eIFf2α in the 
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obese liver [194]. Romain and his colleagues demonstrated that the acyl chain saturation 
could stabilize the dimer of IRE1 and PERK which indicated an activated UPR signaling. The 
change of lipid composition was also able to activate IRE1α and PERK [280].  
In this Chapter, the upregulation by fructose of both ACC and FAS was quite modest 
compared with the results from in vivo study. Consistently, the TG level did not increase 
significantly by fructose treatment. Nevertheless, the impact of betulin on ACC and FAS was 
significant compared with fructose treatment and the levels of ACC and FAS under betulin 
treatment were even lower than the control. These results suggested that betulin 
administration downregulate the DNL in HepG2 cells and this negative effect may not be 
specific to fructose administration. The fold change of p-IRE1 was comparable to that seen 
with HFru feeding in mice (3.3.3). In addition, we observed that p-eIF2α which belongs to 
PERK branch of the UPR was also enhanced by fructose. Different to previous literature 
reports, ER stress was not improved when the lipid synthesize was suppressed by betulin in 
context of high fructose treatment. These results are different from the previous animal study 
(Chapter Chapter 3). This could because the period of betulin treatment was not long enough 
or the dosage was not high enough as there is little literature about betulin on ER stress. 
Further optimization is required. However, these data showed that ER stress would not be 
affected by the change of DNL under certain condition. Moreover, ER stress can be induced 
by fructose in 24 hours while DNL was unaltered in HepG2 cells. This result is supported by 
our current report [250] which showed the ER stress and DNL in the liver occurred 
sequentially in HFru-fed mice. To summary, hepatic ER stress could occur prior to DNL 
under HFru administration although it might be regulated by DNL afterwards.  
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Chapter 6  
 High Fat Diet-induced 
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6.1 Introduction  
High fat (HFat)-feeding animal is a classic model in the research of insulin resistance and type 
2 diabetes. It was originally introduced by Surwit et al. in 1988 [281]. HFat-fed mice showed 
insulin resistance and glucose intolerance with the presence of hyperglycemia and 
hyperinsulinemia [282, 283] which are typical characters of type 2 diabetes in human. Besides 
of the induction of insulin resistance and diabetes, HFat diet also promotes lipid accumulation 
that related to obesity and fatty liver disease. Different from the dietary fructose, dietary fat 
contributes to the triglyceride directly. However, the mechanism is different (Figure 6.1). The 
pathway of dietary fat to triglyceride bypasses the synthesis of saturated of FA which is a 
process defined as de novo lipogenesis (DNL). Critical proteins in DNL such as ACC, FAS 
and SCD1 [284-286] could not be stimulated in high fat (HFat)-fed mice as in HFru-fed mice 
[193].  
Despite excess lipid accumulation, ER stress has been suggested to be another critical factor 
to induce insulin resistance [155]. The impact of ER stress on hepatic insulin resistance has 
been discussed has been discussed in Chapter Chapter 3 and Chapter Chapter 4. Nevertheless, 
it is not clear whether the effect of ER stress on blunted insulin signaling transduction is 
specifically related to HFru diet. To address this question, HFat-fed mice are used as a 
comparison of HFru-fed mice. We hypothesized that ER stress-related impairment of insulin 
signaling transduction in the liver is specific to the HFru diet.  
The HFat diet is known to cause hepatic steatosis by increased extrahepatic lipid supply as 
well as insulin resistance [235, 287]. In current study, HFat-fed mice for either one day or 2 
weeks displayed hepatic steatosis and blunted insulin resistance as HFru-fed mice. However, 
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ER stress was not detected in the HFat-fed mice. These results indicated that ER stress-
induced hepatic insulin resistance is closely related to fructose overconsumption at early stage. 
 
Figure 6.1 Triglyceride synthesis from different nutrition. 
Fructose enters cells through GLUT2 and is further phosphorylated to Fructose-1-P. Fructose-
1-P is converted to pyruvate which then enters mitochondria and is catalyzed to citrate in 
TCA cycle. Once citrate is exported into the cytoplasma, it is converted to saturated fatty acid 
(FA) by stages. The saturated FA with glycerol-3-P can be synthesized to triglyceride. 
Saturated FA could be catalyzed to unsaturated FA which can be also synthesized to 
triglyceride with the presence of glycerol-3-P. Fat from the diet enters the cells as fatty acids. 
The fatty acids are processed into saturated FA to form triglyceride.  
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6.2 Methods 
6.2.1 Animal study 
Male C57BL/6J mice (12 weeks old) from the Animal Resources Centre (Perth, Australia) 
were kept at 22±1°C on a 12h light/dark cycle. After 2 weeks of acclimatization, mice were 
fed for either one day or 2 weeks with either normal chow diet (70% calories from starch, ~10% 
calories from fat, and ~20% calories from protein; Gordon's Specialty Stock Feeds, Yanderra, 
Australia) or high fat (HFat) diet as described in our previous studies [193]. HFat diet was 
provided to the mice from 6pm to 2pm (20 hrs) on the following day when they were 
sacrificed. All experiments were approved by the Animal Ethics Committee of RMIT 
University.  
Body weight and food intake were measured before and after experiments. After one day of 
feeding, the mice were fasted for four hours before the collection of plasma samples for the 
measurement of insulin levels by radioimmunoassay (Linco/Milipore, Billerica, MA) [232, 
238, 248] and glucose levels using a glucometer (AccuCheck II; Roche, Australia). Tissues of 
interest were collected and freeze-clamp immediately for subsequent analyses. Glucose 
tolerance test (GTT; 2g kg-1 BW, i.p.) was conducted in a separate group of mice following a 
four hours fasting and blood glucose levels were measured at 0, 15, 30, 60 and 90 minutes 
using a glucometer (AccuCheck II; Roche, Australia). The area under curve (AUC) was 
calculated to estimate glucose intolerance. For the assessment of insulin signaling in the liver, 
5-7 hour-fasted mice were injected with insulin (2U kg-1 BW, i.p.) 20 min prior to tissue 
collection [193, 232].  
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6.2.2 Measurement of triglyceride levels  
The details were described in 2.1.4.2. 
6.2.3 Western blotting  
The details were described in 2.3. 
6.2.4 Gene expression 
Isolation of RNA from animal tissues 
Mice liver tissues (20~30mg) were homogenized in 1 ml TRIZOL® reagent (Invitrogen, 
Catalog No.15596026) with a power homogenizer. 200 µl of Chloroform (VWR, Catalog 
No.22711324) was added to each homogenate and the mixture was capped securely and 
vigorously hand inverted for 15 seconds followed by incubation at room temperature for 5 
mins. The homogenates were subsequently centrifuged at 13,000x rpm for 15 mins at 4°C. 
The mixture was separated into a lower red, phenol chloroform phase containing protein, an 
interphase containing DNA, and a colourless upper aqueous phase containing RNA. Only the 
RNA-containing upper aqueous phase was transferred to a set of fresh micro-centrifuge tubes, 
and mixed with 500 µl of isopropanol (Sigma-Aldrich, Catalog No.I9516) before another 
centrifuge at 13,000x rpm for 20 mins at 4°C. The RNA precipitate formed a gel-like pellet on 
the bottom side of the tube after centrifugation. The supernatant was removed and the pellet 
was washed twice with 500 µl 75% ethanol (Merck, Catalog No.1.07017.2511). The sample 
was then mixed by vortexing and centrifuged at 13,000x rpm for 5 mins at 4°C. The 
supernatant (ethanol) was removed and the RNA pellet was air dried. At the end of the 
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procedure, the pellet was dissolved in 100 µl Ambion® DEPC-treated water (Invitrogen, 
Catalog No.AM9916) for RNA concentration determination. 
Measurement of RNA concentration 
RNA concentration was quantified by using a NanoDrop Spectrophotometer (Eppendorf 
Thermo Scientific, Australia) at an absorbance of 260/280 nm (A260/280). The NanoDrop 
Spectrophotometer was initialized by 1.0 µl of DEPC water, which was also used as a blank. 
Each RNA sample (1.0 µl) was loaded onto the sampling platform for the measurement of 
RNA concentration. 
Complimentary DNA synthesis by reverse transcription 
Purified RNA with known concentrations was used to generate the complementary DNA 
(cDNA) using a Reverse Transcription System (Bio-Rad Laboratories Inc., USA) with 
random primers according to manufacturer’s instructions. RNA in each of samples was 
diluted to the same final concentration (1 µg/8 µl) by using DEPC water in a sterile 1.5 ml 
eppendorf tube on ice. To remove the original DNA in each sample, RNA and primer master 
mix was prepared (1 µg of RNA templates, 1 µl Dnase I reaction buffer and 1 µl Dnase I 
amplification grade) (Invitrogen, Catalog No.11904-018) in a sterile 1.5 ml eppendorf tube 
and incubated at room temperature for 15 mins. 1 µl of 25 mM EDTA was then added and 
incubated for 10 mins at 65°C. RNA (2 µl from the above sample mix) and a reverse 
transcription master mix (1x reverse transcription buffer, 2x dNTP mix, 1x random primers, 1 
µl reverse transcriptase (Invitrogen, Catalog No.18064-014), DEPC water to a final volume of 
18 µl and they were added to each reaction tube to give a final reaction volume of 20 µl. The 
tubes were then placed in a controlled-temperature heat block and first equilibrated at 25°C 
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for 10 mins, then 37°C for 2 hours, then 85°C for 5 seconds and finally maintained at 4°C. 
The cDNA products from reverse transcription reactions were stored at 4°C to use for real 
time-PCR analysis. 
Real-time polymerase chain reaction 
The cDNA samples were analysed for genes of interest by real-time polymerase chain 
reaction (rt-PCR) using the SYBR Green real-time PCR system (Bio-Rad Laboratories Inc., 
USA). A reaction master mixture (1x IQ SYBR Green Supermix (Bio-Rad Laboratories Inc., 
USA; Catalog No.170-8882), 500 nM primers forward and 500 nM reverse primers, DEPC 
water to a final volume of 24 µl) for each gene of interest was prepared and added to each 1 
µl cDNA samples in a sterile 96-well plate. The plate was placed in a controlled-temperature 
heat block equilibrated at 50°C for 2 mins, 95°C for 3 mins and 40~50 cycles of 95°C for 15 
seconds, 72°C for 30 seconds. The gene expression from each sample was analysed in 
duplicates and normalised against the ribosomal housekeeper gene 18S (GeneWorks, 
Australia). All reactions were performed on the iQTM 5 Real-time PCR Detection System 
(Bio-Rad Laboratories Inc., USA). The results are expressed as relative gene expression using 
the ΔCt method. Primers used for specific genes are listed in Table 14.  
Table 14 Primer sequences for measurements of gene expressions in mice 
Gene Primer sequences 
18S Forwrad:  5’-CGCCGCTAGAGGTGAAATTCT 
Reversed:  5’-CGAACCTCCGACTTTCGTTCT 
SREBP1c Forwrad:  5’-AACGTCACTTCCAGCTAGAC 
Reversed:  5’-CCACTAAGGTGCCTACAGAGC 
ACC Forwrad:  5’-AGGAGATCCGCAGCTTG 
Reversed:  5’-ACCTCTGCTCGCTGAGTGC 
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Gene Primer sequences 
FAS 
Forwrad:  5’- TGCTCCCGACTGCAGGC 
Reversed:  5’- GCCCGGTAGCTCTGGGTGTA 
SCD1 
Forwrad:  5’-CCTCCGGAAATCAACGAGAG 
Reversed:  5’-CAGGACGGATGTCTTCTTCCA 
 
6.2.5 Statistical Analyses 
Data are presented as means ± SE. One-way analysis of variance was used for comparison of 
relevant groups. When significant variations were found, the Turkey-Kramer multiple 
comparisons test was applied. Differences at p<0.05 were considered to be statistically 
significant.  
 
6.3 Results 
6.3.1 HFat diet did not induce DNL in the liver 
Mice were fed a HFat diet for one day or 2 weeks. Bodyweight did not result in any 
significant differences between HFat-fed and CH-fed mice after one day. The HFat-fed mice 
gained significant bodyweight compared with CH-fed mice after 2 weeks (Table 15). 
However, there was no significant different in of caloric intake between groups (Table 15). 
The mature form of the transcription factor SREBP1c was significantly elevated (Figure 6.2 
A). However, the downstream targets of SREBP1c, known as tACC, FAS and SCD1 (Figure 
6.2 B-D, K) were not upregulated compared to control except SCD1. Triglyceride (TG) levels 
in the liver were also examined. As expected, hepatic TG was significantly increased after a 
one day HFat feeding (Figure 6.2 I). To further investigate the effect of HFat diet on hepatic 
DNL, mice were fed with HFat diet for 2 weeks. The mature form of SREBP1c presented an 
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increasing trend in HFat-fed mice but it was not significant (Figure 6.2 E). The expression of 
tACC (Figure 6.2 F) and FAS (Figure 6.2 G) did not show an upregulation in HFat-fed mice. 
In addition, SCD1 (Figure 6.2 H) displayed a significant reduction compared with CH-fed 
mice. These results suggested that HFat diet was incapable to stimulate the DNL in the liver 
by. However, the TG content in the liver was elevated significantly (Figure 6.2 J). This could 
because of the fatty acid influx from the diet. 
Table 15 Basal metabolic parameters of HFat-fed mice. 
 CH HFat (1 day) HFat (2 weeks) 
Body mass (g)    
Day 0 27.0±0.3 26.9 ± 0.4 27.1±0.3 
Day 1 27.1 ± 0.4 27.1 ± 0.4 ND 
Day 14 28.0±0.4 ND 30.0±0.5* 
Caloric intake 
(Kcal/kg.day) 
12.6 ± 1.9 18.0 ± 1.4* 17.1±0.5* 
EPI fat mass (% BW) 1.3±0.1 ND 3.3±0.3* 
Blood glucose (mM) 8.8±0.4 9.2 ± 0.5* 11.8±0.5**# 
Plasma insulin (pg/ml) 203±23 313±64* 371±76**# 
 
Male C57BL/6J male mice were fed either a CH or fat-rich diet (HFru) for either one day or 2 
weeks. Data are means ± SE of 8-10 mice per group. * p<0.05, ** p<0.01 vs CH-fed mice; # 
p<0.05, ## p<0.001 vs HFat (one day feeding). 
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Figure 6.2 HFat diet did not induce DNL in the liver. 
Liver homogenate were extracted for the assessment of the DNL: mSREBP1c (A), tACC (B), 
FAS(C) and SCD1 (D) were determined by immunoblotting was determined and lipogenic 
gene expression following 4 hours of fasting from animals fed with HFat diet for one day. 
mSREBP1c (E), tACC (F), FAS(G) and SCD1(H) were determined by immunoblotting was 
determined following 4 hours of fasting from animals fed with HFat diet for 2 weeks. Tissue 
TG content (I) from animals fed with HFat diet for one day and (J) from animals fed with 
HFat diet for 2 weeks was determined. Data are mean ± SE of 8 mice per group. * p <0.05, ** 
p <0.01; compared with control.  
  
Chapter 6  
 
135 
 
6.3.2 HFat diet was not able to induce ER stress in the liver 
Lipid overload is thought to stimulate ER stress [186, 187]. Hence, we examined whether ER 
stress was activated in HFat-fed mice. Mice were first fed HFat for one day. In contrast to 
feeding a HFru diet, HFat diet did not upregulate the IRE branch of the ER stress as suggested 
by the unaltered levels of p-IRE1 and XBP1 (Figure 6.3 A). Similarly, JNK was not activated 
as revealed by the unaltered p-JNK and t-JNK (Figure 6.3 C). Interestingly, the 
phosphorylation of eIF2α which belongs to the PERK arm of the ER stress response, showed 
a significant increase in HFat-fed mice (~0.5 fold change, p<0.05) (Figure 6.3 B). However 
CHOP, also involved in the PERK pathway, did not increase significantly (Figure 6.3 B). 
When the feeding duration of HFat diet was extended to 2 weeks, a significant increase in 
spliced XBP1 was detected without changin  p-IRE1 (Figure 6.3 D). However, JNK was again 
not activated (Figure 6.3 F). In addition, PERK branch of ER stress was not activated, as 
indicated by the lack of change in both p-PERK and p-eIF2α (Figure 6.3 E).  
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Figure 6.3 HFat diet did not activate UPR in the liver. 
Liver homogenate were extracted for the assessment of the activation of UPR signaling 
pathways. Phosphorylated-IRE1, spliced XBP1 (A), p-eIF2α, CHOP (B) and p-/t-JNK (C) 
were determined by immunoblotting from animals fed with HFat diet for one day. 
Phosphorylated-IRE1, spliced XBP1 (D), p-eIF2α, CHOP (E) and p-/t-JNK (F) were 
determined by immunoblotting from animals fed with HFat diet for 2 weeks. Data are mean ± 
SE of 8 mice per group. * p <0.05, ** p <0.01; compared with control. 
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6.3.3 HFat diet blunted insulin signaling transduction in the liver.  
Excess lipid accumulation is well known to induce insulin resistance [83, 135, 136]. In HFat-
fed animals, blood glucose levels were elevated even after one day feeding and it was further 
upregulated after 2 weeks of high fat (Table 15). HFat-fed mice also exhibited 
hyperinsulinemia from one day to 2 weeks feeding (Table 15). In accordance with this, 
impaired insulin actions, as indicated by the reduced p-Akt response to acute insulin 
stimulation, was detected in the liver. After one day feeding of HFat, p-Akt in response to 
insulin stimulation was significantly downregulated (by 50%) compared to the appropriate 
control (Figure 6.4 A). In addition to the blunted hepatic insulin signaling transduction, mice 
were glucose intolerant, as indicated by the significant increasing incremental area under 
curve (iAUC) from the GTT (Figure 6.4 C). The levels of p-Akt in HFat-fed mice for 2 weeks 
showed further reduction (by 67%). The iAUC from GTT (Figure 6.4 C) consistently showed 
greater change. These data indicating more severe impaired insulin action in the liver (Figure 
6.4 B). As expected, mice developed glucose intolerance as demonstrated by the augmented 
iAUC (Figure 6.4 D).  
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Figure 6.4 Impaired hepatic insulin action in response to HFat feeding. 
Insulin signal transduction was assessed by immunoblotting of key transducer: 
phosphorylated-Akt (serine 473) and total-Akt in whole cell lysate of liver in HFat-fed mice 
for one day (A) and 2 weeks (B). Representative western blots are shown. Glucose tolerance 
test (GTT) was performed with an injection of glucose (2.5 g/kg, ip) after 5-7 hours of fasting. 
GTT curve and iAUC, incremental area under the curve for blood glucose level from HFat-
fed mice for either one day (C) or 2 weeks (D). Data are mean ± SE of 8 mice per group. * p 
<0.05, ** p <0.01; compared with control.  
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6.4 Discussion 
Hepatic insulin resistance can be triggered via different mechanisms [130] [131, 132] [157-
160]. HFru-related ER stress has been demonstrated to contribute to this disorder in previous 
chapters. However, mice fed with a HFat diet displayed insulin resistance and glucose 
intolerance after one day without the activation of ER stress. This observation suggests that 
there may be other factors to trigger hepatic insulin resistance in HFat-fed mice at early stage.  
In this chapter, mice were fed a HFat diet for either one day or 2 weeks. As expected, hepatic 
triglyceride content showed significantly elevated on both one day and 2 weeks feeding. 
However, DNL was not upregulated, in contrast to the response to a HFru diet. After one day 
feeding with HFat diet, both tACC (p=0.06) and FAS (p<0.05) tend to be reduced without a 
significant change in SCD1. When the feeding duration lasted for 2 weeks, SCD1 was 
significantly suppressed by HFru, while tACC and FAS showed a decreasing trend. These 
results are consistent with our previous studies [193] and further confirms that exogenous 
supply of FAs in the HFat diet impair DNL [288]. Intriguingly, the mature form of SREBP1c 
was not downregulated, unlike its downstream targets (e.g. ACC and FAS). This may be due 
to the activation of SREBP1c being dependent on proteolytic cleavage [289] and, that this 
process is affected by fatty acids [290]. In addition, SREBP1c is suggested to respond to 
insulin [60], and may thus enhanced by the high plasma insulin levels associated with HFat-
fed mice.  
Lipid-related ER stress has been discussed in previous chapters (1.6.2). The HFat-fed mice 
exhibited significant increase of triglyceride in the liver. However, the IRE1 branch of the 
UPR did not show any activation, as indicated by unaltered p-IRE1 and sXBP1. Moreover, p-
JNK did not exhibit activation. Phosphorylated-eIF2α, a downstream protein of PERK, was 
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significantly increased in HFat-fed mice, but by only about 50%. In addition, CHOP, another 
downstream protein in the PERK branch did not exhibit a significant difference between chow 
and HFat fed mice. Despite a remarkable increase in sXBP1, p-IRE1, p-eIF2α or CHOP was 
not upregulated in response to a HFat-fed mice. These data suggested that HFat diet was 
unable to completely induce ER stress in the liver after 2 weeks. However, some studies have 
previously demonstrated that HFat-induced obesity induced by long-term HFat feeding is 
closely related to ER stress. ER stress is detected in the liver of obese humans and is reduced 
after weight loss [291]. Similarly, mice that fed a HFat diet for 16 weeks developed hepatic 
ER stress, indicated by increased p-PERK and p-eIF2α [125]. This maybe because the lipid 
accumulation in our model was not enough to trigger ER stress. However, it has been reported 
that animals fed for HFat diet for 3 days can develop insulin resistance in the liver [45, 254]. 
These results indicated that there are other factors rather than ER stress to initiate insulin 
resistance in HFat-fed mice model. 
This study also excluded the possibility that the activation of IRE1 branch in HFru-fed mice 
was due to the hyperinsulinemia. IRE1 and XBP1 are suggested to be able to upregulate by 
insulin [158]. However, both HFat- and HFru-fed mice displayed hyperinsulinemia while only 
HFru-fed mice showed upregulated ER stress.  
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This chapter will summarise the major findings of the studies that have been performed in this 
thesis, and reach the overall conclusions from these findings. I will also discuss the limitations 
of the studies in this thesis and propose future studies to address remaining issues. 
 
7.1 Major findings 
Type 2 diabetes is one of the most prevalent chronic diseases worldwide, of which insulin 
resistance is a key metabolic defect [2, 38, 39]. Many studies have suggested the link of 
excess lipid accumulation, stress and insulin resistance, and have investigated the potential 
mechanisms responsible for lipid or stress contributing to insulin resistance [244]. However, 
the exact pathways of the development of insulin resistance are not fully understood. 
Understanding the molecular mechanisms leading to insulin resistance is required, for the 
improved development of therapeutic treatments for type 2 diabetes. This thesis focused on 
the suggested role of ER stress and lipid accumulation on hepatic insulin resistance. 
As described in 1.5 and 1.6, the relationship between ER stress, lipid accumulation and 
insulin resistance are complicated because the effects that these factors have on each other. In 
this thesis, acute and 2 weeks HFru-feeding models were developed to explore the 
mechanisms underlying the pathogenesis of this disorder. As well as the capability of high fat 
diet to induce insulin resistance [282], fructose over-consumption has been proposed to be 
another potential trigger of impaired insulin action [225]. Therefore, both HFru and HFat diets 
were applied to mice in this project.  
In acute feeding with either HFru or HFat diet, mice showed impaired insulin signaling 
transduction in the liver. In addition, HFat-fed mice were glucose intolerant, while HFru-fed 
mice showed normal glucose tolerance, indicating different metabolic mechanisms between 
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mice fed the different diets. HFru-, but not HFat-fed, mice displayed ER stress. The 
subsequent studies focused on the HFru diet, which could upregulate ER stress and insulin 
resistance simultaneously. When I investigated the insulin activated signaling pathways, 
namely phosphorylated IRS1 and Akt, the results showed blunted signaling only in the liver, 
but not in peripheral skeletal muscle or adipose tissue, indicating that liver is the first site to 
develop insulin resistance during HFru feeding. These results are consistent with studies in 
rodents in which HFat-induced whole-body insulin resistance is initiated by impaired hepatic 
insulin action, and aggravated by skeletal muscle insulin resistance [45, 254]. All these 
studies indicated that the liver plays a critical role in the initial development of insulin 
resistance and thus we focused on studying hepatic metabolism.  
In addition to the activation of ER stress/UPR, hepatic DNL, which may then lead to lipid 
accumulation from carbohydrate, was rapidly initiated. I hypothesised that the activation of 
IRE1 was associated with both upregulated DNL and impaired insulin action. ER stress is 
suggested to induce hepatic insulin resistance by increasing DNL [180] and directly 
interfering with insulin signaling via the activation of JNK [158]. The key role for IRE1/JNK 
in triggering hepatic insulin resistance induced by HFru feeding was supported by the finding 
that inhibition of IRE1 activation by the chemical chaperone TUDCA was able to block 
activation of JNK, IRS1 serine phosphorylation and preserve the insulin-stimulated 
phosphorylation of Akt. The unaltered PKCε activity in HFru-fed mice indicated that the 
initial hepatic insulin resistance may be independent of DAG accumulation.  
In summary, Chapter Chapter 3 showed for the first time that HFru diet is able to induce ER 
stress in the acute phase, and that the activated ER stress (mainly in the IRE1 branch of this 
phenomenon) is closely related to the development of insulin resistance in the liver. Prior to 
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this study, ER stress was suggested not to be a direct causal factor in hepatic insulin resistance 
[162]. In this study, we observed that suppression of ER stress pathways by TUDCA, a 
chemical chaperone, could improve impaired insulin action in the liver, while there was no 
change on other insulin resistance associated pathways, such as PKCε activation and lipid 
accumulation. Interestingly, we demonstrated that IRE1/XBP1 was the first UPR pathways 
activated arm n response to HFru diet, while the PERK arm was significantly induced only 
after 3 days HFru-feeding. These results indicated that IRE1 branch is more closely associated 
with initial hepatic insulin resistance rather than PERK branch. 
The mechanism by which fructose induces ER stress is not yet clear. The possibility that the 
hyperinsulinemia induced by HFru diet could upregulates IRE1 and XBP1 is unlikely, as 
HFat-fed mice did not have ER stress, but remained hyperinsulinemic. The possible pathways 
involved in HFru-induced insulin resistance may be related to the mTOR [292] signaling and 
activation of autophagy [293, 294]. 
This thesis also used a longer term feeding model of HFru-diet induced insulin resistance to 
mimic the pathological condition in humans. In addition to the suppression of insulin 
signaling pathways in the liver, glucose intolerance indicated by significantly reduced iAUC 
was also detected. Moreover, HFru-fed mice displayed significantly higher fasting blood 
glucose levels. All the data indicated that mice that were fed with HFru for an extended period 
developed a more severely impaired insulin action. As expected, hepatic ER stress and DNL 
were both enhanced by HFru-feeding. JNK phosphorylation was unaltered in response to 
IRE1 activation challenging the role of JNK in mediating insulin resistance. This led us to 
explore other possibilities. I examined hepatic DAG and ceramide levels which are known 
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triggers of insulin resistance. The data showed that DAG levels significantly increased, while 
ceramide displayed the opposite trend in HFru-fed mice.  
These results indicated that DAG may play a pivotal role for insulin resistance, rather than ER 
stress, in this HFru-feeding model. To further confirm this hypothesis, fenofibrate (FB) was 
administrated to downregulate lipid synthesize and determine its impact on insulin action. As 
expected, we found a significant reduction in DAG levels as well as TG content in the liver. 
Blunted insulin signaling was restored, and glucose tolerance was improved with FB 
treatment. Interestingly, ER stress was remarkably elevated in response to FB. Both 
IRE1/XBP1 and PERK/eIF2α arms signaling activated. These findings suggest that lipid 
accumulation (mainly DAGs), rather than the activation of JNK or IKK, is pivotal for ER 
stress to trigger hepatic chronic insulin resistance. Therefore, by reducing the accumulation of 
deleterious lipids, hepatic insulin resistance can be ameliorated against increased ER stress. 
JNK and IKK, which are able to interfere with IRS can be activated by different pathways in 
the context of insulin resistance, not limited to ER stress [155, 295]. In the acute model, JNK 
activation was diminished when IRE1 phosphorylation was reduced in HFru-fed mice with 
TUDCA treatment, suggesting that activated JNK was associated with the upregulation of 
IRE1. However, the mechanism of the loss of JNK activation in HFru-fed mice in this model 
is not yet clear. In addition, JNK remained unaltered when IRE1 was markedly increased by 
FB treatment. This latter response might be due to FB itself suppressing JNK phosphorylation 
[296].  
In the HFru study, DAG levels exhibited trend to increase following longer period of feeding. 
This change of DAG became a major contributor of hepatic insulin resistance, surpassing the 
negative regulation of IRE1-JNK pathways. This explanation is supported by a study in which 
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mice lacking XBP1 (IRE1 substrate) fed a fructose diet for 1 week exhibited increased hepatic 
insulin sensitivity during clamp despite the activation of hepatic ER stress markers and of 
JNK [162].  
Since ER stress and DNL both play an important role in the development of insulin resistance 
in the liver, I investigated the relationship between ER stress and DNL in a cultured cell 
model. Fructose, rather than common inducers of ER stress (tunicamycin or thapsigargin), 
was used to induce ER stress to maintain a consistency with HFru feeding showed in vivo. 
Similar to what found in vivo, both ER stress and DNL were induced in response to fructose 
administration in vitro. Betulin was added to suppress DNL by inhibiting the cleavage of the 
lipogenic transcription factor SREBP1c. These results showed that the suppression of 
lipogenesis did not affect the activation of ER stress by fructose, indicating that the induction 
of ER stress could be independent of excess lipid content.  
 
SUMMARY & CONCLUSIONS 
Based on the results obtained from this thesis, a number of conclusions can be drawn as 
follows: 
In the context of HFru-feeding, hepatic insulin resistance could result from ER stress and/or 
excess lipid accumulation in the liver. The underlying mechanisms are different over time. In 
acute conditions (one day), HFru diet stimulated ER stress and upregulated DNL in the liver. 
Increased ER stress was suggested from IRE1/XBP1 activity. Consequently, JNK was 
induced, which then interfered with IRS function, to block insulin signaling pathways. 
However, the IRE1-mediated activation of JNK, rather than lipid accumulation, appears to 
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play a more critical role at the onset of hepatic insulin resistance induced by HFru feeding (as 
indicated by results obtained from the very short term study).  
HFru diet induced XBP1 activation promoted DNL, which then led to hepatic lipid 
accumulation and impaired insulin action. As the feeding period extended from one day to 2 
weeks, the negative effect of lipid accumulation in the liver through the induction of DNL 
became more severe. The accumulation of lipid metabolites (such as DAGs) attenuated 
normal insulin signal transduction leading to hepatic insulin resistance, resulting in a 
reduction in glucose tolerance. Meanwhile, the lack of activation of JNK suggested that JNK 
function was not required for ER stress-related hepatic insulin resistance in long term HFru-
feeding. Intriguingly, PPARα activation induced by FB administration may also directly 
stimulate DNL, perhaps dependent on signaling from IRE1 and PERK branches. Despite this, 
the predominant effect triggered by PPARα was to potentiate oxidative capacity and to 
eliminate lipid accumulation, thus overcoming fructose-induced hepatic insulin resistance (IR) 
and glucose intolerance. 
In summary, the predominantly negative effect of JNK activation induced by IRE1 might be 
overcome by the persistently increasing lipid accumulation, possibly becomes a secondary 
inducer of insulin resistance in the long term. The findings from this study here suggest that 
IRE1 may be a potential target for pharmacological treatment of insulin resistance in the liver 
induced by high fructose consumption.  
 
7.2 Future directions 
PPARα activation is closely related to lipid metabolism which has been suggested to be linked 
to ER stress. The study in Chapter 4 demonstrated an association between PPARα activation 
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and ER stress in the liver. The upregulation of ER stress with FB administration was 
accompanied by elevation in both lipid synthesize and oxidation. However, the role of PPARα 
in these changes needs more investigation. The preliminary data from this lab suggest that 
PPARα activation plays an essential role in the FB-induced ER stress and lipogenesis. Further 
studies will need to examine how PPARα activation induces ER stress in a PPARα knockout 
mice model.  
Studies undertaken in this thesis demonstrate that the ER stress rather than excess lipid plays a 
dominant role in blunting hepatic insulin signaling pathway in response to HFru consumption. 
However, excess lipid accumulation following longer period of feeding became more critical 
to develop hepatic insulin resistance in HFru-fed mice. ER stress appears to be able to drive 
DNL rather than being induced by excess lipid. In addition, I found that HFat diet with the 
same feeding period as HFru diet was not able to induce ER stress. All the results indicated 
that the contribution of ER stress on the initiation of insulin resistance in the liver is nutrition-
specific in a given period. Therefore, further studies are warranted to understand the 
mechanism of how fructose triggers ER stress. Over the past decade, increasing evidence 
shows that autophagy is closely associated with ER stress in the liver [297, 298]. Genetic 
ablation of autophagy proteins leads to hepatic ER stress and insulin resistance [299]. More 
recently, the crosstalk between ER stress and mTOR signaling pathway has been of a great 
interest in the field  [292]. It has been suggested that mTOR interferes with ER stress by 
regulating protein synthesize in the short term [292, 300]. As mTOR has been shown to be 
induced by HFru feeding [301] and has been shown to correlate with autophagy, it is 
reasonable to expect that mTOR and autophagy pathways may be involved in the link 
between fructose consumption and ER stress. According to the preliminary data from our 
laboratory, mice could be fed with HFru diet to activate mTOR or autophagy pathways. 
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Inhibitors of either mTOR or autophagy could be administrated to mice to interfere with these 
pathways. Their simultaneous impact on of ER stress could aslo be investigated. The outcome 
of such studies might then provide further insight into mechanisms of dietary fructose in 
insulin resistance and the metabolic syndrome. The significance of this work not only lies in 
bridging gaps in our current understanding but also provides a scientific basis for drug design 
and discovery for the prevention and treatment of type 2 diabetes. 
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